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The Protein Kinase C (PKC) family consists of at least 10 different isoforms 
that are subdivided into three groups:  “classical/conventional” cPKCs (, I-II and ), 
“novel” nPKCs (, ,  and ) and “atypical” aPKCs ( and 	/
). The nPKCs are 
“novel” because they do not respond to changes in calcium levels as do the classical 
PKCs, but respond only to changes in diacylglycerol levels.  This work elucidates 
several aspects of the V5 domain’s role in nPKC function through the use of PKC-
and - truncation mutants, as well as two reciprocal PKC- and - C-terminal chimeras: 
PKC-/V5 and PKC-/V5.  First, the ability of the V5 domain to confer isoform-
specific function was tested by overexpressing chimeric PKC mutants in 32D cells.  
Overexpression of wild-type PKC-, but not PKC-, mediated macrophage 
differentiation in this cell line upon stimulation with TPA.  However, neither PKC-
/V5 nor -/V5 were able to confer a TPA-inducible macrophage differentiation 
phenotype to 32D cells, indicating that PKC- V5 domain was essential to this 
isoform-specific function, but not sufficient to transfer its activity to PKC-. Second, 
nPKC mutants were utilized to determine the ability of the V5 domain to modulate 
kinase activity.  PKC chimeric and truncation mutants had significantly decreased 
kinase activity in vitro compared to their wild-type counterparts.  PKC-/V5 and -
/V5 lacked phosphorylation at critical phosphorylation priming sites, a likely cause 
of their reduced kinase activity.  Glutamic acid substitutions made at unphosphorylated 
priming sites, either individually or in combination, did not rescue kinase activity.  
Stimulation with TPA increased the level of phosphorylation only at sites that were 
already phosphorylated.  The lack of phosphorylation and kinase activity are likely due 
to differences in phosphatase activity, since both PKC- and - V5 chimeras bound the 
upstream, activating kinase, Phosphoinositide-dependent Kinase-1.  In conclusion, 
changes to the V5 domain of PKC- and - disrupted the proteins’ phosphorylation 
status and kinase function which, in turn, likely prevented conferral of isoform-specific 
function in a macrophage differentiation assay with PKC- and - V5 chimeras. 
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1INTRODUCTION 
PKC Structure
The Protein Kinase C (PKC) enzymes are a family of related serine/threonine 
protein kinases within the AGC Kinase superfamily that are important for the 
transduction of numerous cell signals from the plasma membrane to the nucleus of the 
cell.  PKCs are also responsible for coordinating various signaling pathways, 
modulating gene expression, and inducing cytoskeletal changes and other cell 
biological processes.  PKC expression and activation have been linked to cell 
proliferation, differentiation, adhesion, cell cycles and other cell functions.  Not 
surprisingly, PKC plays an important role in cancer biology.  
There are at least 10 structurally related isoenzymes of PKC grouped into three 
separate classes based upon the structure of their regulatory domains:  the conventional 
or classical PKCs (, I, II, and ), novel PKCs (, , , and ) and atypical PKCs 
(	/
 and ).  All PKC isoforms require phosphatidylserine (PS) for optimal activity.  
Conventional PKCs (cPKCs) can be activated by calcium and/or by diacylglycerol 
(DAG) and phorbol esters.  Novel PKCs (nPKCs) are not regulated by calcium but can 
be activated by DAG and phorbol esters.  Finally, atypical PKCs (aPKCs) are 
unresponsive to calcium as well as to DAG and phorbol esters.  
All isoforms of PKC have constant (C) and variable (V) domains (Figure 1). 
2Figure 1.  Structure of Protein Kinase C Isoforms.  Constant domains (C1-C4) and variable 
domains (V1-V5) are shown.  The phorbol esters and the second messenger DAG bind to the cysteine-
rich (CR) motif present in cPKCs and nPKCs.  C2 domains bind calcium except for nPKCs which have a 
modified (“C2”) domain; PS, pseudosubstrate sequence; C3, ATP-binding domain; C4, kinase domain.  
The C3, V4 and C4 domains are often combined into one large kinase domain which defines PKC 
members within the AGC kinase superfamily. 
3Each of the constant domains of PKC has at least one known function.  Indeed, more is 
known about those domains that all PKCs have in common than about what makes 
each isoenzyme unique.   Each PKC isoform has an amino(N)-terminal regulatory 
domain and a carboxyl(C)-terminal catalytic domain.  The first isozymes were cloned 
in the mid-1980s and their sequences revealed four conserved domains:  C1-C4 [1].  
The C1 domain contains cysteine-rich motifs that serve as sites for DAG and phorbol 
ester binding [2].  The C2 domain allows conventional PKCs to bind to phospholipids 
in a calcium-dependent manner [3].  Novel PKC isoforms have a modified C2 domain 
that does not bind calcium.  Very recent work by Stahelin et al. has shown that PKC-
’s C2 domain does not bind to phospholipids, either [4].  Instead, it appears that the 
C2 domain of PKC- is a phosphotyrosine binding domain [5]. The C3 and C4 
domains of the catalytic region of the protein comprise the ATP-binding site and the 
substrate binding site, respectively [6].  The C3, V4 and C4 domains are often 
combined and increasingly considered as one large kinase domain that defines PKC 
members within the AGC kinase superfamily.  The regulatory and catalytic domains 
are connected by a hinge region (V3) that is subject to proteolysis when the enzyme 
becomes membrane-bound [7]. 
 
PKC Activity and Regulation
PKC transduces a myriad of signals that begin with lipid hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol and inositol 1,4,5-
trisphosphate (IP3).  The dogma has been that the generation of DAG at the plasma 
4membrane recruits PKC from the cytosol and induces an allosteric change in the its 
conformation, opening up the enzyme to permit substrate binding and signaling to the 
next level [8].  While this scheme may be generally true for the classical PKCs, there is 
substantial evidence that indicates that the mechanism of PKC activation is far more 
complex and that novel PKC activation and regulation may work quite differently from 
classical PKC activation [9, 10].  
It is believed that all PKC isoforms are rendered mature only after a series of 
priming phosphorylations.  Our knowledge of these priming phosphorylations has been 
derived in large part from studies of their function in classical PKC isotypes [11-13].  
These priming phosphorylations occur at three conserved sites within the catalytic 
domain.  Two of the three sites are found within the V5 domain. The first, and perhaps 
most critical, priming site is at the activation loop (Figure 2).  Phosphorylation at this 
site aligns and stabilizes the two lobes of the kinase domain in preparation for catalysis 
[14].  Mutations to the activation loop site profoundly block classical PKC activities 
[15, 16].  However, unlike classical PKCs, the novel PKC- does not require this 
phosphorylation for catalytic competence, although catalytic activity is reduced when 
the activation loop is not phosphorylated [17].  
Phosphoinositide-dependent protein kinase 1 (PDK-1) has been shown to 
phosphorylate classical, novel as well as atypical PKCs at the activation loop site [10, 
18].  Accumulating evidence shows that in mammalian cells PKCs are constitutively 
phosphorylated at the activation loop, although this site can become dephosphorylated 
in PKC- and - in quiescent, serum-starved cells.  In this case phosphorylation 
5Figure 2.  Alignment of activation loop, turn motif and hydrophobic motif phosphorylation sites in 
murine PKC- and -. The schema of Protein Kinase C on top shows the relative positions of the 
phosphorylations for PKC- and - respectively.  Phosphorylation sites are in bold and their respective 
motifs are underlined. 
6at this site quickly occurred upon stimulation with serum or platelet-derived growth 
factor [10, 19]. 
Phosphorylation at the activation loop leads to rapid phosphorylation at the 
second priming site within the proline-rich “turn motif” (Figure 2).  This is an 
autophosphorylation site for conventional PKC isoforms [20] as well as the novel 
isoforms PKC- [21] and - [10]. This phosphorylation site is thought to lie at the apex 
of a turn on the upper lobe of the kinase domain.  Phosphorylation of the turn motif 
appears to lock the enzyme into a stable, catalytically competent conformation that is 
resistant to phosphatase activity [12, 22].  The known 3D structure of PKC’s cousin, 
PKA, suggests that the phosphorylated residue at this site serves to anchor the V5 
domain to the upper lobe of the kinase domain [23]. 
The mechanism of phosphorylation at the final priming site, the hydrophobic 
motif site (Figure 2), seems to be dependent upon the isoform.  For classical isoforms 
the final priming step is again an autophosphorylation event.  However, the same may 
or may not be true of novel PKC- and -. Work by Cenni et al. has indicated that the 
hydrophobic motif priming site in PKC- (S729) might be an autophosphorylation site 
based on the following evidence:  first, wild-type PKC- overexpressed in HEK 293 
cells was phosphorylated at this site but a kinase-deficient PKC- construct was not; 
second, PKC- was phosphorylated at S729 in the absence of any other kinase in an in 
vitro kinase assay; third, phosphorylation at this site was reduced in cells incubated 
with a novel PKC inhibitor [10]. 
However, other groups are casting light on what may be a much more context-
dependent phenomenon.  Rybin et al. have used cardiac myocytes to demonstrate a 
7dynamic and tightly-controlled regulation of phosphorylation within the hydrophobic 
motif of PKC- that appears to be under the control of PKC- [24].  Parker and his 
colleagues have shown that the hydrophobic motif phosphorylation site on PKC- is 
regulated by a heterologous kinase, perhaps PKC- [25], in 293 cells.   In a separate 
study by the same group, phosphorylation at the hydrophobic motif of PKC- and -
was shown to be downstream of mTOR (mammalian Target of Rapamycin) on an 
amino acid sensing pathway [19].  Regardless of the mechanism used, this 
phosphorylation site appears to remain exposed until it becomes phosphorylated, and it 
serves as a docking site for PDK-1 in the unphosphorylated state [26].  Once 
phosphorylated and buried, the hydrophobic motif contributes to the stability of the 
active enzyme [3]. 
Once mature, PKC is ready to respond to changes in cofactor concentrations.  
Increases in DAG or phorbol ester levels recruit novel PKC molecules to membranes 
where they undergo an allosteric change that releases the pseudosubstrate domain from 
the catalytic half of the protein. This open conformation is then free to bind to co-
localized substrates.  Once bound to its target, PKC phosphorylates serine and 
threonine residues, usually within basic sequences.  A very short consensus sequence 
has been deduced: S/T-X-K/R [27] where X is any amino acid.  In some cases two 
amino acids appear between the critical phosphorylation site and the conserved lysine 
or arginine residue. 
In addition to the translocation induced by changes in second messenger levels 
and (in the case of at least novel PKCs) the dynamic regulation of the priming 
phosphorylations, PKC activity is also regulated by a battery of binding partners and 
8anchoring proteins [28].  These proteins can act as scaffolds, positioning PKC near the 
proper substrates.  They may also act as anchors, keeping PKC in place in long enough 
to co-localize with regulators such as other kinases, phosphatases or organelle-specific 
proteins.  A large variety of PKC-binding proteins have already been identified:  
STICKs (Substrates that Interact with C-Kinases), cytoskeletal proteins such as actin 
and tubulin, scaffolding proteins such as AKAPs (A-Kinase Anchoring Proteins) and 
certain caveolin isoforms as well as RACKs (Receptors of Activated C-Kinases) [9].  
To date, RACKs have only been identified for the PKC-, - and - isoforms, and in 
each case the respective RACK protein is known to serve other functions in addition to 
PKC binding [29-31]. 
Biologically, PKCs play a role in receptor desensitization [32], transcriptional 
regulation [33], the modulation of membrane structure events [34], and the regulation 
of cell proliferation [35] and differentiation [36], among other things.  Phorbol esters 
such as 12-O-tetradecanoylphorbol-13-acetate (TPA) have often been utilized to 
stimulate such PKC-related effects.  For example, the human myeloid cell lines, HL-60 
and U937, stopped dividing and differentiated along the monocytic lineage when 
stimulated by TPA [37, 38], whereas TPA stimulation increased proliferation in human 
SNU-C1 and SNU-C4 colon cancer cell lines [39].  PKC activation was implicated in 
these studies, since it is the major intracellular receptor for phorbol esters [40]. 
Yet the lack of a means to directly detect activation of specific PKC isozymes 
in vivo stands as a large roadblock in evaluating the role of individual PKC isozymes in 
such systems.  To study isozyme-specific effects upon differentiation and proliferation, 
one can examine the subcellular localization of isozymes upon differentiation or 
9introduce kinase-defective isoforms as dominant-negative mutants.  Overexpression of 
specific PKC isoforms can also be utilized to identify isoform-specific function.  For 
example, CHO cells that overexpress PKC- reduced their growth rate in the absence 
of TPA and were arrested in the G2/M phase in the presence of TPA [41].  In contrast 
PKC- overexpression in rat fibroblasts induced evidence of neoplastic transformation, 
such as anchorage-independence and increased cell proliferation [42].  Although 
examples can be found to the contrary, the literature generally has borne out a 
“differentiating” or “apoptotic” role for PKC- and a “proliferative” or “oncogenic” 
role for PKC-.
Experiments conducted in the Mushinski lab with these isoforms are in 
agreement with this isoform-specific phenotypic pattern.  In 32D cells, a mouse 
promyeloid cell line, overexpression of PKC- or PKC- resulted in macrophage-like 
differentiation in response to TPA stimulation, whereas overexpression of PKC-II, -,
- and - with TPA stimulation did not [36].  The differentiation of 32D cells was 
assessed by several criteria:  morphology, surface adherence, lysozyme production, 
pahgocytosis and macrophage-specific cell surface markers.  Specifically, TPA 
treatment of 32D cells overexpressing PKC- dramatically increased cell volume, 
induced surface adherence in roughly 25-33% of the cells and resulted in Mac-1 and 
Mac-3 expression at the cell surface.  Mac-1 (CD11b, CD18) is predominantly 
expressed on myeloid and natural killer cells, where it mediates numerous 
physiological functions, including phagocytosis of foreign particles, migration and 
adhesion of leukocytes to the endothelium and activation of neutrophils and monocytes 
[43].  Mac-3 is also involved in cell adhesion and serves as a marker for peritoneal 
10 
macrophages [44].  In contrast, overexpression of PKC- in NIH 3T3 cells stimulated 
cell proliferation, increased growth to saturation density and induced anchorage-
independent growth.  These overexpressing cells grew as tumors in nude mice [35, 42]. 
Examples of TPA-stimulated myeloid cell differentiation are certainly not 
limited to 32D cells.  Normal mouse peritoneal monocytes and the human cell lines 
HL-60 and U937 are able to differentiate upon TPA stimulation alone [36].  These cells 
generally express easily detectable levels of PKC- and - and low levels of PKC-
and -, yet it remains unknown whether a specific PKC isoform is responsible for the 
TPA-induced differentiation.  In contrast, 32D cells express endogenous PKC-, -, -
and -µ. Overexpression of PKC- in these cells seems to upregulate endogenous PKC-
 expression, whereas overexpression of PKC- expression downregulates endogenous 
PKC- expression (data not shown).  Other changes in endogenous PKC expression 
resulting from overexpression of PKC- or - in 32D cells have not been tested. 
 
Lessons from PKC Constructs and Mutants
The oncogenic and differentiating potential of overexpressed PKC- and - has 
been mapped to their respective catalytic domains with chimeric mutants that consist of 
the regulatory domain of one isoform fused to the catalytic domain of the other.  
Experiments with these chimeras, designated PKC- and -, revealed that the 
catalytic domain of PKC- imparted oncogenic characteristics to the protein when 
overexpressed in NIH 3T3 cells activated by TPA stimulation [45].  Fibroblasts that 
overexpressed the PKC- chimera showed decreased doubling time and the ability to 
11 
grow in soft agar [45].  The overexpressed PKC- chimera retarded cell growth and 
mediated phorbol ester-induced differentiation of promyelocytes into macrophages 
[46]. 
Lessons from these chimeras were not limited to growth and differentiation 
assays.  Translocation studies revealed that, in the absence of TPA, overexpressed 
PKC- and PKC- in NIH 3T3 cells localized mainly in the cytoplasm, although 
immunostaining showed some PKC- and  in and on the nucleus [45].  Upon TPA 
stimulation both overexpressed enzymes translocated mainly to the plasma membrane, 
while the staining on and in the nucleus remained unchanged [45].  The same study 
showed that prior to stimulation, PKC- and - were present mostly in the perinuclear 
region, and, after one hour of treatment with TPA, both isoforms were found on/in the 
nucleus. 
That the subcellular localization and the translocation patterns of PKC- and -
 were similar to that of PKC- and -, respectively, is likely not a coincidence.  
Because the PKC substrate consensus sequence is not very specific, PKC isoform 
specificity is achieved by restricting PKC isoforms to substrates within certain 
subcellular locales.  As already mentioned, any number of PKC binding partners may 
assist in isoform-specific localization.  For example, p32 (gC1qBP) has been identified 
as a RACK for PKC-, localizing it to the perinuclear region upon TPA stimulation 
[31].   p32’s exact function is not known, but it is involved in mitochondrial function 
[47, 48], transcription [49] and splicing factor modulation [50].  The beta-coatamer 
protein -COP’ has been identified as a RACK for PKC-, localizing PKC- to Golgi 
vesicles where it is involved in Golgi budding and vesicular trafficking [51].  These 
12 
binding partners may account for at least part of the translocation patterns observed in 
NIH 3T3 cells overexpressing these isoforms.  P32 specifically may play an important 
role in PKC-’s isoform-specific function, since it may be preferentially drawing PKC-
 to the perinuclear region in this context.  However, it is not clear that PKC-
localization to the nuclear membrane is required for 32D macrophage differentiation, 
and p32’s known involvement in mitochondrial function or splicing do not indicate 
what kind of a role, if any, the p32-PKC- complex may play in this cellular assay. 
 
V5 Domain Studies
The size of the PKC V5 domain has not been established functionally for the 
novel PKCs.  The original PKC domain boundaries were established by Coussens et al. 
in 1986 when only three conventional isoforms of PKC were known [1].  At that time 
the V5 domain was considered to consist of approximately the most C-terminal seven 
amino acids, depending upon the isoform.  Sequence comparison of all ten PKC 
isoforms has generally fit the original loose description of constant and variable 
regions, and the nomenclature has persisted.  Functionally, however, it has been shown 
that deletion of the last 15 amino acids of the V5 domain of PKC-, expressed in yeast, 
rendered the enzyme biologically inactive in vivo and catalytically inactive in vitro 
[52].  However, a PKC/IIV5 chimera was then constructed in which the most C-
terminal 73 amino acids of PKC-II replaced the final 77 amino acids of PKC-. This 
chimera was found to restore PKC activity in yeast as demonstrated by increased 
calcium uptake in response to TPA stimulation and modulation of cell doubling time 
13 
by TPA [53].  A similar chimeric construct was found to translocate to the nucleus and 
phosphorylate lamin B – functions specific to PKC-II [54]. 
Differences between the PKC isoforms I and II also provide insight into the 
size and function of the V5 region.  The two isoforms are splice variants that differ 
only in the V5 region (here defined as the carboxyl most 50-52 amino acids).  PKC-I
and II translocate to distinct subcellular locations when activated in the same cell type 
[55, 56].  In addition, Blobe et al. showed that PKC-II, but not -I, specifically bound 
to actin upon TPA treatment [55].  Goodnight et al. showed co-localization of PKC-II 
with actin upon TPA stimulation, while PKC-I translocated from the cytoplasm to the 
plasma membrane upon similar treatment [56].  These studies and others have shown 
that the V5 domain of PKC-I and -II is associated with different physiological 
functions [57].  Consistent with such data, Staudinger et al. have shown that in PKC-,
the V5 domain contains a PDZ-binding domain which allows it to bind PICK1 protein 
[58].  PDZ domains are protein-protein interaction motifs that serve to localize proteins 
to specific subcellular sites [59-61] and have been implicated in PKC signaling 
pathways related to phototransduction [62].  PKC interacts with PDK-1 through 
binding with the hydrophobic motif in the V5 domain [63].  In addition, proteins and 
complexes, including mTOR, atypical PKC isotype specific interacting protein (ASIP) 
and PKC- have been shown to bind to the V5 domain of one PKC isoform or another. 
The present body of work seeks to determine the role of the V5 region in PKC-
 and - maturation, activation and biological function.  Because previous V5 region 
studies have focused mainly on conventional isoforms, little is known about the 
function of the V5 region in the novel isoforms  and . Nevertheless, much is known 
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about the role of PKC- and - in cellular function, and studies with PKC- and - 
regulatory/catalytic chimeras have indicated that isoform-specific function was 
conferred by the catalytic half of the protein which includes the V5 domain [45, 46].  
Moreover, two out of three critical priming phosphorylation sites have been mapped to 
this domain [64], yet their role in PKC function remains an area of active debate.  
Therefore the results of this study fill a gap in our knowledge of the role of PKC 
variable domains and provide a functional definition for the novel PKC V5 region.  
The findings from the experiments reported here were designed to elucidate the role of 
the V5 structural domain in conferring isozyme specificity.  However, the results shed 
light on the role of the V5 domain in broader aspects of nPKC function and regulation, 
including kinase activity and post-translational modification. 
Table 1 lists constructs made for use in determining the role of the V5 domain 
in PKC function.  Not all constructs were used and not all those constructs used were 
included in every experiment. 
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Table 1.  A list of constructs used in this project and a short description of each. 
PKC Construct Tag Description 
PKC- GFP or HA Wild type 
PKC- GFP or HA Wild type 
PKC-/V5 GFP or HA PKC- w/ V5 domain exchanged with that of PKC-
PKC-/V5 GFP or HA PKC- w/ V5 domain exchanged with that of PKC-Q
PKC- CD11 GFP or HA PKC- w/ C-terminal deletion of 11 amino acids 
PKC- CD24 GFP or HA PKC- w/ C-terminal deletion of 24 amino acids 
PKC- CD54 GFP or HA PKC- w/ C-terminal deletion of 54 amino acids 
PKC- CD6 HA PKC- w/ C-terminal deletion of 6 amino acids 
PKC- CD20 GFP or HA PKC- w/ C-terminal deletion of 20 amino acids 
PKC- CD50 HA PKC- w/ C-terminal deletion of 50 amino acids 
PKC-/23 GFP or HA PKC- w/ terminal exon PKC- exchanged with that of PKC-
PKC-/18 GFP or HA PKC- w/ terminal exon PKC- exchanged with that of PKC-
PKC- T505E GFP PKC- activation loop mutant (ALM) 
PKC- S643E GFP PKC- V5 turn motif mutant (TMM) 
PKC- S662E GFP PKC- V5 hydrophobic motif mutant (HMM) 
PKC- DM GFP PKC- ALM + HMM double mutant 
PKC- TM GFP PKC- ALM + TMM + HMM triple mutant 
PKC- T566E GFP PKC- activation loop mutant 
PKC- T710E GFP PKC- activation loop mutant 
PKC- S729E HA PKC- V5 hydrophobic motif mutant 
PKC- DM GFP PKC- ALM + HMM double mutant 
PKC- TM GFP PKC- ALM + TMM + HMM triple mutant 
PKC-/V5 T505E GFP PKC-/V5 activation loop mutant 
PKC-/V5 T566E GFP PKC-/V5 activation loop mutant 
PKC-/V5 DM GFP PKC-/V5 ALM + HMM double mutant 
PKC-/V5 DM GFP PKC-/V5 ALM + HMM double mutant 
PKC-/V5 TM GFP PKC-/V5 ALM + TMM + HMM triple mutant 
PKC-/V5 TM GFP PKC-/V5 ALM + TMM + HMM triple mutant 
PKC- CD24 T505E GFP PKC- w/ C-terminal deletion of 24 amino acids + ALM 
PKC- CD54 T505E GFP PKC- w/ C-terminal deletion of 54 amino acids + ALM 
PKC- CD6 T566E HA PKC- w/ C-terminal deletion of 6 amino acids + ALM 
PKC- CD6 S729E HA PKC- w/ C-terminal deletion of 6 amino acids + HMM 
PKC- CD6 DM HA PKC- w/ C-terminal deletion of 6 amino acids + ALM + HMM 
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Specific Aims
1. Construction of expression vectors with HA-tagged and GFP-tagged PKC 
V5 domain chimeric and truncation mutants. 
2. Establishment of 32D and NIH 3T3 cell lines that carry the above vectors.  
3. Determination of ability of V5 domain to mediate 32D cell differentiation 
and NIH 3T3 cell transformation. 
4. Testing whether the PKC V5 domain modulates kinase activity. 
5. Assessing the ability of the V5 domain to alter PKC priming 
phosphorylation status. 
6. Determination whether TPA can restore wild-type phosphorylation status to 
PKC V5 domain mutants. 
7. Assessment of glutamic acid substitution as a priming phosphorylation 
substitute in novel PKC isoforms. 
8. Determination whether PKC V5 chimeras can bind PDK-1. 
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METHODS AND MATERIALS 
 
Wild-Type and Mutant PKC Constructs
Site-Directed Mutagenesis 
 
Plasmids containing PKC-, -, -/V5 and -/V5 [65] were obtained from 
Qiming Wang, NCI.  PKC-/V5 contained a point mutation in the codon for amino 
acid 239 (VA).  Site-directed mutagenesis was performed with Quickchange Site-
directed mutagenesis kit (Stratagene, La Jolla, CA) and the following primers: forward 
(F), TTC AAG GAG ATT GAC TGG TCC CTC CTG GAG; reverse (R), CTC CAG 
GAG GGA CCA GTC AAT CTC CTT GAA. 
Site-directed mutagenesis was also employed to change critical priming 
phosphorylation sites from codons for serine or threonine to one encoding glutamic 
acid within many of the PKC wild-type, chimeric and truncation fusion proteins.  The 
primers used and the corresponding amino acid substitutions are as follows:  PKC-
T505E,  (F) GGC CGG GCC AGC GAG TTC TGC GGC ACT, (R) AGT GCC GCA 
GAA CTC GCT GGC CCG GCC; PKC-T566E, (F) GGC GTG ACA ACT ACC 
GAG TTC TGT GGG ACT CCT, (R) AGG AGT CCC ACA GAA CTC GGT AGT 
TGT CAC GCC;  PKC-S643E, (F) GAA TGA GAA ACC TCA GCT TGA GTT 
CAG TGA CAA GAA CCT CAT CG, (R) CGA TGA GGT TCT TGT CAC TGA 
ACT CAA GCT GAG GTT TCT CAT TC; PKC-T710E, (F) CGC GGG AAG AGC 
CAA TAC TTG AGC TTG TGG ATG AAG CAA TC, (R) GAT TGC TTC ATC 
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CAC AAG CTC AAG TAT TGG CTC TTC CCG CG; PKC-S662E, (F) GCC TTC 
CAT GGC TTC GAA TTT GTG AAT CCC AAG, (R) CTT GGG ATT CAC AAA 
TTC GAA GCC ATG GAA GGC; PKC-S729E, (F) GAA TTT AAA GGC TTC 
GAA TAC TTT GGT GAA G, (R) CTT CAC CAA AGT ATT CGA AGC CTT TAA 
ATT C; PKC-CD6S729E, (5’) TTA CAT GGT ACC TTG GTA GTG TTC AAT 
GGC CTT CTT AAG ATC AAA ATC TGC G, (3’) GCC GCG AAT TCA AAA GTA 
CTC GAA GCC TTT AAA TTC. 
 
PCR Amplification and Cloning of Wild-Type PKC- and - as well as Their 
Derivative Chimeric and Truncation Mutants 
 
The wild type, chimeric and truncated PKC constructs were subsequently 
amplified from pLTR-PKC-, -, -/V5 or pCRII-PKC-/V5 with 250 ng of plasmid 
and 10 pmol of each primer as appropriate by PCR:  10 min, 94°C; 15-24 cycles of 1 
min at 94°C, 1 min at 60°C and 3 minutes at 72°C; 10 min at 72°C; hold at 4°C.  The 
Platinum Pfx PCR Kit (Invitrogen, Carlsbad, CA) with Pfx Polymerase and the 
appropriate buffer and nucleotides was used with each reaction.  The primers used in 
the construction of the HA-tagged PKCs included a KpnI site at the 5’ end and an 
EcoRI site at the 3’ end for ligation. The primers used in the construction of the GFP-
tagged PKC- constructs were the same as those for the HA-tagged constructs except 
for the 5’ primer that included an EcoRI site: TTA CAT GAA TTC TTG GTA GTG 
TTC AAT GGC CTT CTT AAG ATC AAA ATC TGC G. Primers were not needed in 
the construction of the GFP-tagged PKC- constructs, as they could be excised from 
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the pHM6 vector with HindIII and EcoRI and ligated directly into pEGFP-C2.  Primer 
sequences were as follows:  pHM6-PKC-, (F) TTA CAT GGT ACC TTG GCA CCC 
TTC CTG CGC ATC TCC TT, (R) ATA TGA ATT CTT AAA TGT CCA GGA ATT 
GCT CAA ACT TGG GAT TCA CAA AGG AG; pHM6-PKC-/V5, (F) TTA CAT 
GGT ACC TTG GCA CCC TTC CTG CGC ATC TCC TT, (R) ATA TGA ATT CAG 
GGC ATC AGG TCT TCA CCA AAG TAG GA; pHM6-PKC-, (F) TTA CAT GGT 
ACC TTG GTA GTG TTC AAT GGC CTT CTT AAG ATC AAA ATC TGC G, (R) 
ATA TGA ATT CAG GGC ATC AGG TCT TCA CCA AAG TAG GA; pHM6-PKC-
/V5, (F) TTA CAT GGT ACC TTG GTA GTG TTC AAT GGC CTT CTT AAG 
ATC AAA ATC TGC G, (R) ATA TGA ATT CTT AAA TGT CCA GGA ATT GCT 
CAA  ACT TGG GAT TCA CAA AGG AG; pHM6-PKC-CD11, (F) TTA CAT GGT 
ACC TTG GCA CCC TTC CTG CGC ATC TCC TT, (R)  ATA TGA ATT CAA 
AAG GAG AAG CCA TGG AAG GCT TCC TGG; pHM6-PKC-CD24, (F) TTA 
CAT GGT ACC TTG GCA CCC TTC CTG CGC ATC TCC TT, (R)  ATA TGA ATT 
CAG ATG AGG TTC TTG TCA CTG AAG GAA AGC TGA G; pHM6-PKC-CD54, 
(F) TTA CAT GGT ACC TTG GCA CCC TTC CTG CGC ATC TCC TT, (R) ATA 
TGA ATT CAG GGC TTA AAG GGC GGC TCC ACC TTC; pHM6-PKC-CD6, (F) 
TTA CAT GGT ACC TTG GTA GTG TTC AAT GGC CTT CTT AAG ATC AAA 
ATC TGC G, (R) ATA TGA ATT CAA AAG TAG GAG AAG CCT TTA AAT TCT 
TCC TGG TTG ATC TGC; pHM6-PKC-CD20, (F) TTA CAT GGT ACC TTG GTA 
GTG TTC AAT GGC CTT CTT AAG ATC AAA ATC TGC G, (R) ATA TGA ATT 
CAA ATG ATT GCT TCA TCC ACA AGT GTA AGT ATT GGC TCT TCC; pHM6-
PKC-CD50, (F) TTA CAT GGT ACC TTG GTA GTG TTC AAT GGC CTT CTT 
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AAG ATC AAA ATC TGC G , (R) ATA TGA ATT CAC GGC TTG AAG GGG 
GGC TTG ATT TTC TTC TG.  The amplicons were then cloned into the pEGFP-C2 
(Clontech, San Diego, CA) and pHM6 (Roche, Indianapolis, IN) mammalian 
expression vectors. 
 
Construction of New V5 Chimeras Based on Genomic Structure 
 
The Exon 1-17/1-22 and Exon18/23 fragments of PKC- and -, respectively, 
were obtained using PCR with primers directed to the 5’ and 3’ ends of the PKC- and 
- fragments.  The sequences and locations of the primers were as follows:  for the 
PKC-(Exon1-17) fragment, 
TTACATGGTACCTTGGCACCCTTCCTGCGCATCTCCTT (Del5’KpnI) and 
CACTTTGGGCTTAAAGGGCGGCTCCAC (17R); for the PKC-(Exon 18) 
fragment, AAATCCCCTTCAGACTACAGCAAC (18F) and 
ATATGAATTCTTAAATGTCCAGGAATTGCTCAAACTTGGGATTCACAAAGG
AG (Del3’EcoRI); for the PKC-(Exon1-22) fragment, 
TTACATGGTACCTTGGTAGTGTTCAATGGCCTTCTTAAGATCAAAATCTGCG 
(Epi5’KpnI) and AATTCTCGGCTTGAAGGGGGGCTTG (22R); for the PKC-
(Exon 23) fragment, AAAACCAAAAGAGATGTCAATAACTTTGAC (23F) and 
ATATGAATTCAGGGCATCAGGTCTTCACCAAAGTAGGA (Epi3’EcoRI) 
200 ng of the cloned pHM6-PKC- and - were used as templates.  PCR conditions 
were the same as were used for the making of the other constructs.  The PKC-/23
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and -/18 constructs were obtained by blunt end ligation of the  and  fragments 
followed by a second round of PCR amplification using these 5’ and 3’ primers: 
pHM6-PKC-/23, (F) TTA CAT GGT ACC TTG GCA CCC TTC CTG CGC ATC 
TCC TT, (R) ATA TGA ATT CAG GGC ATC AGG TCT TCA CCA AAG TAG GA; 
pHM6-PKC-/18 (F) TTA CAT GGT ACC TTG GTA GTG TTC AAT GGC CTT 
CTT AAG ATC AAA ATC TGC G, (R) ATA TGA ATT CTT AAA TGT CCA GGA 
ATT GCT CAA ACT TGG GAT TCA CAA AGG AG; pEGFP-C2-PKC-/18, (F) 
TTA CAT GAA TTC TTG GTA GTG TTC AAT GGC CTT CTT AAG ATC AAA 
ATC TGC G, (R) ATA TGA ATT CTT AAA TGT CCA GGA ATT GCT CAA ACT 
TGG GAT TCA CAA AGG AG.  The pEGFP-C2-PKC-/23 construct was made by 
digesting and excising the PKC-/23 insert from the pHM6 vector with HindIII and 
EcoRI and re-ligating it into the pEGFP-C2 vector that had been digested with the 
same restriction enzymes. 
 
Sequence Verification 
 
Sequence verification of all constructs was performed by cycle-sequencing in a 
Hybaid PCRExpress thermal cycler with 200-500 ng template, 3.2 pmol primer and 8 
µl of Terminator Ready Reaction Mix, (Applied Biosystems, Foster City, CA) in a total 
volume of 20 µl.  Reaction cycle was as follows:  1 min at 96°C followed by 25 cycles 
of 96°C for 30 sec, 50°C for 15 sec, 60°C for 4 min followed by a final cycle at 60°C 
for one minute.  Sequencing reactions were submitted to the NCI Sequencing Mini-
Core, and the results were analyzed/verified with SequencerTM 4.2.2 software. 
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Cell Culture
32D and WEHI-3 cells were obtained from Linda Wolff, NCI, NIH.  NIH 3T3 
and Rat-2 cells were provided by Douglas Lowy, NCI, NIH.  HEK 293 cells were 
obtained from Beverly Mock, NCI, NIH.  COS-7 and CHO-K1 cells were purchased 
from American Type Culture Collection (Manassas, VA).  All cells were cultured at 
37°C with 5% carbon dioxide, 100 U/ml penicillin, 100 µg/mL streptomycin and 200 
µM L-glutamine (Biosource, Camarillo, CA).  32D cells were grown in RPMI 1640 
medium with 10% fetal calf serum (Hyclone, Logan, UT), 10% WEHI-3-conditioned 
medium (source of IL-3) and 50 mM -mercaptoethanol (Sigma, St. Louis, MO).  
COS-7 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) with 10% 
Fetal Calf Serum.  NIH 3T3 cells were grown in DMEM with 10% Calf Serum 
(Invitrogen, Carlsbad, CA).  CHO-K1 cells were grown in F-12 Nutrient Mixture 
(Invitrogen) and 10% fetal calf serum. 
 
Overexpression of PKC Fusion Proteins in 32D, COS-7, NIH 3T3, CHO-K1, RAT-2 
and HEK 293 Cells
1 x 107 32D cells in 1 ml of Electroporation Buffer (10 mM NaPO4, 1 mM 
MgCl2, 250 mM sucrose – pH 7.4) were transfected with 20 µg DNA by 
electroporation with a BTX Electro Square Porator ECM 830 set at 350 V, for two 99 
µs pulses one second apart.  These cells were selected for 2 weeks in medium 
supplemented with 0.5 µg/ml G418 (GIBCO) and then cloned by limiting dilution.   
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Rat-2, NIH 3T3, CHO-K1, COS-7 and HEK 293 cells were all transiently transfected 
as appropriate for each cell line according to the Polyfect protocol from Qiagen 
(Valencia, CA). 
 
Western Blot Analysis
Cells were pelleted and lysed in RIPA buffer (50 mM Tris-pH 7.4, 150 mM 
NaCl, 1% Triton-X 100, 1% Sodium Deoxycholate, 0.1% SDS) with Protease Inhibitor 
Cocktail III and Phosphatase Inhibitor Cocktails I and II (Calbiochem, San Diego, CA).  
5X Loading Buffer (0.025% SDS, 200 mMTris-HCl-pH 6.8, 50% glycerol 0.2 M 
dithiothreitol and 0.05% (w/v) bromophenol blue) was added to each sample and 
samples were boiled at 95°C for 5 minutes and stored at -20°C.  Proteins were 
separated on 4-20% acrylamide gradient tris-glycine Novex gels (Invitrogen, Carlsbad, 
CA) and transferred onto nitrocellulose membranes (Schleicher & Schuell, Keene, 
NH).  Membranes were blocked for 15-20 min with 5% (w/v) nonfat, dried milk in 
TTBS.  Membranes were incubated with primary antibody overnight at 4°C, washed 3 
times with TTBS and then incubated with secondary antibody conjugated with 
horseradinsh peroxidase for 1 hr at room temperature.  Immunoreactivity was 
visualized using SuperSignal ® West Pico chemiluminescence detections system 
(Pierce, Rockford, IL). 
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Differentiation Assays
Morphology 
 
32D cells were treated with 100 nM TPA for 8 hours to induce macrophage 
differentiation.  To assess morphology, cytospins of 2-5 x 105 TPA-treated and 
untreated cells were stained with Diff-Quick (American Scientific Products, McGaw 
Park, IL), and images were collected using an upright bright-field microscope (Zeiss 
Axiophot, Thornwood, NY) under high magnification.  The microscope is fitted with 
an MTI 3CCD camara and Scion Image 1.62c software (Scion Corp, Frederick, MD).  
 
Flow Cytometry Analysis 
 
1 x 106 32D cells, with or without 8-hr treatment with 100 nM TPA, were 
incubated with anti-Mac1 (CD11b) and anti-Mac-3 (M3/84) antibodies (BD 
Biosciences, San Diego, CA) conjugated with FITC at 4°C for 30 min.   Cells were 
subsequently analyzed for surface expression of these antigens using a Becton 
Dickinson FACScan (San Jose, CA).  Cells incubated without antibodies or with an 
irrelevant isoype-matched antibody, FITC anti-mouse CD45R/B220 (BD Biosciences), 
were used as negative controls. 
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Confocal Fluorescence Microscopy
Prior to observation, transiently transfected NIH 3T3 cells were washed 
twice with standard medium (DMEM without phenol red supplemented with 1% FBS) 
pre-warmed to 37°C.  TPA was diluted to 1 µM concentration in the same medium.  To 
image live cells, a Bioptechs Focht Chamber System (FCS2) was inverted and attached 
to the microscope stage with a custom stage adapter in the confocal minicore (Center 
for Cancer Research, National Cancer Institute, NIH).  NIH 3T3 cells, cultured on a 40-
mm round coverslip, were introduced into the chamber system, which was connected 
to a temperature controller set at 37°C, and medium was perfused through the chamber 
with a Model P720 microperfusion pump (Instech, Plymouth Meeting, PA).  Sequential 
images of the same cell were collected at 1-min intervals using LaserSharp software 
through a Bio-Rad MRC 1024 confocal scan head mounted on a Nikon Optiphot 
microscope with a 60X planapochromat lens (Melville, NY).  Excitation at 488 nm was 
provided by a krypton-argon gas laser with a 522/32 emission filter for green 
fluorescence. 
 
Kinase Assays with Full-Length Substrate
Immunoprecipitated proteins were washed 3 times in kinase buffer (20 mM 
Tris, pH 7.5, 5 mM MgCl2 and 0.1% NP40), aliquoted into 2 tubes, each containing 20 
µl of Protein G-sepharose beads:  One tube was used for the kinase assay itself and one 
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tube for Western blotting.  The immunoprecipitates were then resuspended in 20 µl of 
reaction buffer with 0.015 mM cold ATP, 0.2 µCi/µl 32P-ATP (Amersham-Pharmacia, 
Piscataway, NJ), 1 µg Histone H1 or Myelin Basic Protein, 1 µM TPA, 
phosphatidylserine, and 0.2 mM DTT).  Reactions were allowed to proceed for 30 min. 
at 30° C, except where otherwise noted.  Reactions were stopped by addition of 
Western sample buffer and immediately loaded onto polyacrylamide gels.  Gels were 
stained with Gelcode Blue (Pierce, Rockford, IL), photographed, and then wrapped in 
plastic wrap exposed to X-ray film at room temperature for 4-18 hours.  Spot 
densitometry readings were taken with the Fluorchem™ 8000 system by Alpha 
Innotech Corp., San Leandro, CA).  Integrated density values for vector alone were 
considered background and subtracted from values for experimental samples. 
 
Kinase Assays with Biotinylated Peptide Substrates
Immunoprecipitated proteins were washed three times in kinase buffer (above), 
aliquoted into 4 tubes, each containing 10 µl of Protein G-sepharose beads:  3 tubes for 
kinase assay replicates and one tube for Western blotting.  The immunoprecipitates 
were then resuspended in 20 µl of reaction buffer recommended by the Calbiochem 
PKC Assay Kit:  0.015 mM cold ATP, 0.2 µCi/µl 32P-ATP (Amersham-Pharmacia, 
Piscataway, NJ), 0.025 mM biotinylated PKC pseudosubstrate, 0.5 mM CaCl2, 10 mM 
MgCl2, 20 mM Tris-HCl pH 7.5, and an activator micell suspension solution composed 
of 0.3 mg/ml PS, 0.03 mg/ml DAG and 0.3% Triton X-100.  Reactions were allowed to 
proceed for 30 min. at 30° C, unless otherwise noted, and were stopped by the addition 
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of 10 µl of 8.0 M guanidine hydrochloride.  Labeled pseudosubstrate was bound to a 
membrane within a centrifugal ultrafiltration unit that was washed and added directly 
to scintillation fluid for counting. 
 
Immunoprecipitation
All PKC constructs and GFP were immunoprecipitated from HEK or CHO cell 
lysates in the presence of 2 µl anti-GFP (BD Biosciences), 40 µl Protein G-sepharose 
and 750 µl RIPA buffer with Protease Inhibitor Cocktail III (Calbiochem) and 
Phosphatase Inhibitor Cocktails I + II (Calbiochem).  Sepharose beads were washed 
three times with 400 µl of kinase buffer (5 mM MgCl2, 1% NP40 and 20 mM Tris, pH 
7.5).  Immunoprecipitated proteins were separated by SDS-PAGE and transferred to 
Protran nitrocellulose membranes (Schleicher & Schuell).  
 
Co-immunoprecipitation
PDK-1 was immunoprecipitated with 30 µl of protein G-sepharose beads, 2 µl
rabbit anti-PDK-1 Ab (#3062, Cell Signaling) from HEK cells lysed with 20 mM Tris 
(pH 7.9), 137 mM NaCl, 5 mM EDTA, 1 mM EGTA, 10 mM NaF, 10% glycerol, 1% 
Triton-X 100 and Protease Inhibitor Cocktail III (Calbiochem, San Diego, CA).  The 
above contents were tumbled overnight at 4° C.  Immunoprecipitation complexes were 
then washed 1X in lysis buffer, 1X in high salt buffer (20 mM HEPES, 500 mM NaCl, 
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0.1% Triton-X 100, 10% glycerol) and finally 2X in low salt buffer (20 mM HEPES, 
150 mM NaCl, 0.1% Triton-X 100 and 10% glycerol). 
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THE ROLE OF THE V5 DOMAIN IN CONFERRING ISOFORM-SPECIFIC 
FUNCTION 
 
Expression of Wild-Type, Chimeric and Truncated PKCs in 32D Cells
In cell differentiation and cell transformation assays, PKC- and - isoform-
specific function was previously mapped to the C-terminal half those isoforms [45, 46].  
Those experiments have been summarized in the Introduction.  In the following 
experiments, PKC- and - V5 chimeras and truncation mutants were designed, 
constructed and tested within the context of 32D cell differentiation assays to see if 
isoform-specificity could be mapped more precisely to the most carboxyl-terminal 
(V5) domain of these nPKC isoforms. 
PCR-generated PKC-, -, -/V5, -/V5 as well as PKC- and - C-terminal 
truncation mutants were first subcloned into the pHM6 mammalian expression vector 
for generation of HA epitope-tagged proteins.  Figure 3 depicts the V5 sequences for 
the chimeric and truncation mutants utilized throughout this study.  The truncation 
mutants were designed to include either both, one or none of the phosphorylation 
priming sites located within the V5 domain.  The entire V5 domain has been deleted in 
the most truncated PKC- and - mutants.  The sequences exchanged between the 
chimeras include all of the V5 domain as well as a short sequence of approximately 15 
amino acids just upstream with > 81% homology/62% identity at the amino acid level. 
To determine the role of the V5 domain in conferring the isoform-specific 
ability of PKC- to induce 32D promyeloid cells to differentiate into macrophage cells,
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Figure 3.  V5 sequence of wild-type murine PKC- and - and their derivative mutants.  Turn motif 
and hydrophobic motif phosphorylation sites are boxed.  Underlined sequence just upstream of the V5 
domain was included in the chimeric exchange as a structural link between the two variable domains.  
“CD” followed by a number indicates a C-terminal deletion of the indicated number of amino acids. 
31 
32D cell clones expressing truncated and chimeric PKC mutants were selected and 
tested.  Because levels of protein expression may affect protein function in cells, we 
sought lines of 32D cells that stably expressed relatively equal amounts of HA-PKC 
fusion protein.  Figure 4 shows the results of a representative Western blot of PKC-
expressing clones.  This blot is a compilation of those clones with the most comparable 
levels of PKC expression as determined by staining with anti-HA, anti-PKC- and anti- 
PKC- antibodies.  32D cells overexpressing PKC-, - and -/V5 were readily 
obtained.  However, 32D cell clones overexpressing comparable amounts of PKC-
/V5 and PKC truncation mutants were much more difficult to find, even after 
intensive screening of at least 25 clones per construct.  No endogenous PKC- was 
found in 32D cells, but a small amount of endogenous PKC- could be seen with the 
anti-PKC- antibody.  
 
32D Cell Differentiation
32D cells are bi-potential promyelocytic cells capable of differentiating into 
either granulocytes or macrophages depending upon the conditions.  32D cells that 
overexpress PKC-, but not those that overexpress PKC-, differentiate into 
macrophages in the presence of TPA [36].  Mischak et al. showed that overexpressed 
wild-type PKC- in 32D cells could induce macrophage differentiation upon 
stimulation with as little as 16 nM TPA for anywhere from 4-18 hours [36].  In this 
system differentiation starts out with adhesion of greater than 90% of the 32D cells to 
the bottom of the culture dish.  After several hours of TPA stimulation, most cells have
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Figure 4.  Western blot determination of mutant PKC expression in 32D cell clones.  Overexpressed 
proteins, indicated at the top of each lane, were stained with either anti-HA or an anti-N-terminal 
Generally, 15 µg of total protein lysate was loaded in each lane.  PKC- or anti-PKC- antibody.  
Staining for actin shows that equal amounts of total protein were loaded in each lane.  Positions of 
protein size standards are shown to the left. 
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returned to their suspended state, but a large fraction remain adherent and have 
upregulated macrophage-specific surface markers as described in the Introduction.  In 
addition, these cells have increased lysozyme production and are capable of ingesting 
yeast cells [36]. 
Wang et al. later showed that this PKC--specific ability was conferred to a 
PKC- chimera that has a PKC- regulatory domain and a PKC- catalytic domain 
[46].  With the knowledge that this isoform-specific ability was localized to the 
catalytic domain, we decided to see if this PKC--specific function could be further 
mapped to the V5 domain.  As a starting point, 32D cell lines overexpressing wild-type 
PKC- and - as well as the PKC- and - V5 chimeras were stimulated with 100 nM 
TPA for 7 hours to see if either chimera would mediate 32D cell differentiation.   
 Histological analysis of those lines tested showed that only PKC--
overexpressing 32D cells acquired macrophage-like phenotypic features:  large cells 
with complex plasma membrane structures and numerous cytoplasmic vacuoles (Figure 
5, Panel D).  Interestingly, PKC- overexpressing 32D PKC- cells are less polarized 
than cells overexpressing other PKCs before TPA stimulation (Figure 5, Panels A,C,E, 
G, and H).  32D PKC-/V5 cells seem somewhat enlarged after TPA treatment 
(Figure 5, Panel H) and a small portion of 32D PKC-/V5 cells have extended 
pseudopodia, as have 32D PKC- cells (Figure 5, Panels D and J). Although all 32D 
cells showed an increase in adherence to the bottom of the cell culture dish shortly after 
TPA stimulation, only PKC--overexpressing cells continued to adhere to the bottom 
of the cell culture dish after 7 hours of TPA stimulation (data not shown). These 
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Figure 5.  Morphology of wild-type and chimeric PKC overexpressers after stimulation with TPA.  
32D Lines that express PKC-, -, /V5 and -/V5 were treated with 100 nM TPA for 7 h.  The cells 
were applied to uncoated glass microscope slides using cytocentrifugation and then stained with Giemsa.  
Photographs of representative fields were taken using a light microcope with a 40X objective.  Data are 
from one of three similar experiments, all of which showed clear evidence of macrophage morphology 
only in the TPA-treated wild-type PKC- overexpressing cells.
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adherent cells showed a flattened, polarized morphology, similar to that seen in Figure 
5, Panel D.  In summary, the morphology data indicate that PKC--specific 32D cell 
differentiation could not be attributed to PKC-’s V5 domain, since overexpression of 
either chimera induced certain morphological features indicative of a partial and 
unconvincing macrophage differentiation phenotype. 
FACS analysis for surface markers characteristic of macrophages also indicated 
that the V5 domain within the context of PKC- and - V5 chimeras was unable to 
mediate 32D cell differentiation (Figure 6).  While PKC--overexpressing 32D cells 
showed an increase in Mac-1 and Mac-3 expression after stimulation with TPA, PKC-
-, -/V5- and -/V5-overexpressing cells did not (Figure 6).  Both sets of results 
suggested that the V5 domain of PKC- was indeed important for conferring isoform-
specific function since a PKC- molecule with an altered V5 domain was unable to 
induce macrophage differentiation.  However, the PKC- V5 domain was not sufficient 
to confer the isoform-specific function to PKC- within the context of a PKC-/V5 
chimera.  Longer treatments with higher doses of TPA were also unable to induce 
macrophage differentiation in any but the PKC--overexpressing 32D cell lines (data 
not shown). 
 It has already been shown that 32D cell differentiation occurs only in the 
presence of overexpressed PKC- [36].  To ensure that 32D cell differentiation was 
not, however, dependent upon the level of PKC- overexpression, 32D cells were 
transfected cells with PKC- under the control of three different promoters: a 
metallothionine (MTH) and a long terminal repeat (LTR) promoter, in addition to the 
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Figure 6.  Flow cytometry analysis of 32D cells overexpressing wild-type and V5 chimeric PKCs.  
Cells were treated with (solid lines) or without (dashed lines) 16 nM TPA for 10 h and stained with 
FITC-labeled antibodies against Mac-1 and Mac-3. 
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cytomegalovirus (CMV) promoter present within the pHM6 plasmid.  This was an 
important control, inasmuch as some of the mutants and chimeric constructs achieved 
variable levels of exogenous PKC expression.  The LTR promoter-driven PKC-
plasmid generated the highest level of PKC- protein and the metallothionine promoter 
the least (Figure 7).  The resulting cells with varying levels of PKC- overexpression 
were then assayed for differentiation. All three cell lines were capable of differentiating 
upon TPA stimulation as evidenced by expression of Mac-3 (Figure 7) and as 
evidenced by histology (data not shown).  The results of this experiment suggest that 
even moderate levels of PKC V5 chimera expression would be enough to induce 
macrophage differentiation in 32D cells if the chimera were capable of doing so. 
 
32D Cell Proliferation Rates
Wang, et al. previously reported that PKC--overexpressing 32D cells showed 
a slower rate of proliferation than untransfected 32D cells or 32D cells overexpressing 
PKC- [46].  In the same report, this isoform-specific phenomenon was shown to be 
conferred by the catalytic half of the PKC- molecule in the context of PKC- and -
regulatory/catalytic domain chimeras.  To see if this isoform-specific function could be 
conferred by the V5 domain, proliferation rates were recorded for 32D cells 
overexpressing wild-type as well as PKC- and - V5 chimeras.  Measured in 
duplicate, the results suggest that there is no difference in proliferation rate between 
32D cells expressing wild-type vs. mutant PKC constructs (Table 2).  The earlier 
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Figure 7.  Mac-3 stains positive on TPA-treated PKC--overexpressing 32D cells indicating 
macrophage differentiation occurs regardless of levels of PKC- expression  A.  Western blot of 
32D cell lysates obtained before TPA treatment and developed with anit-PKC-. Lane 1, untransfected 
32D cell lysate.  Lanes 2, 3 and 4, 32D cells overexpressing varying amounts of PKC- protein.  Lane 2,
PKC- expressed from the pHM6 vector (H-) has a slightly higher molecular weight because this 
protein is fused to an amino terminal hemaglutinin tag. Lane 3, PKC- expression with a metallothionine 
promoter (M-).  Lane 4, PKC- expression with a long terminal repeat promoter (L-).  B. Flow 
cytometric analysis of the same cells before (gray) and after (black) 6 h treatment with 50 nM TPA. 
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Table 2.  Doubling time of 32D cells overexpressing wild-type and V5 chimeric PKCs.  Results in 
bold are the average of two experiments (individual results shown in parentheses). 
Cell Line Doubling Time (h) 
32D HA vector 12.5 (11.5, Expt. 1; 13.5, Expt. 2) 
32D HA-PKC- 13.6 (13.3, Expt. 1; 13.9, Expt. 2) 
32D HA-PKC- 13.8 (15.8, Expt. 1; 11.8, Expt. 2) 
32D HA-PKC-/V5 13.4 (16.4, Expt. 1; 10.4, Expt. 2) 
32D HA-PKC-/V5 10.4 (10.9, Expt. 1; 9.8, Expt. 2) 
40 
experiments were performed with PKC- and - clones that expressed extremely high 
levels of exogenous PKC.  It is likely that the level of expression achieved with the 
pHM6 vector was not high enough to induce phenotypic changes without the addition 
of TPA stimulation. 
 
Summary of the V5 Domain’s Ability to Confer Isoform-Specific Function
The V5 domain was shown to be essential for PKC function:  the exchange of 
the V5 domain abrogated PKC-’s ability to mediate macrophage differentiation.  
However, the PKC- and - V5 chimeras were unable to confer isoform-specific 
function in the 32D differentiation assay.  Similarly, exogenously expressed PKC-
truncation mutants did not induce 32D cells to differentiate upon TPA stimulation.  
PKC- truncation mutants and the PKC-/V5 chimera were difficult to express at 
levels similar to wild-type PKC- within this cell line.  Thus, even small deletions 
within the V5 domain or the exchange of the V5 domain among novel PKC isoforms 
were enough to cause large differences in PKC regulation and function.  Further 
experiments were needed to elucidate the mechanism(s) responsible for those 
differences. 
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THE V5 DOMAIN OF PROTEIN KINASE C- AND - MODULATES KINASE 
ACTIVITY 
PKC Translocation
One possible explanation for the inability of the PKC- and - V5 chimeras to 
confer isoform-specific function could be a lack of kinase activity in the unnatural 
chimeric proteins.  This seemed unlikely since chimeric PKCs have been used with 
success before (see Introduction).  Nevertheless, even slightly reduced kinase activity 
in the V5 chimeras might explain the lack of conferral of isoform-specific function 
already observed (Chapter 3).  We therefore chose to determine the kinase activity of 
the chimeric and truncated PKCs relative to wild-type PKC- and -.
PKC is thought to be active only in response to changes in second messenger 
concentrations (or phorbol esters) which enable the enzyme to translocate - with help 
from PKC binding proteins - from its resting state in the cytosol to the plasma 
membrane or other known targets.  With this in mind, PKC translocation studies were 
chosen as a starting point for determining PKC mutant activity.  Figure 8 shows the 
subcellular localization of exogenous PKC constructs in the absence of TPA, as well as 
the TPA-induced translocation pattern of GFP-tagged PKC-, -, -/V5 and -/V5.  
All constructs were present in the cytosol before TPA stimulation; GFP-PKC- and -
/V5 showed increased nuclear fluorescence due to the nuclear localization signal 
present within the PKC- V5 domain.  After TPA addition, PKC- rapidly translocated 
to the plasma and nuclear membranes, whereas PKC- translocated only to the plasma 
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Figure 8.  Translocation of GFP-tagged wild-type and chimeric PKCs in response to TPA in NIH 3T3 
cells.  Cells were imaged every minute for a total of 20 min following the introduction of 1 µM TPA 
with images indicated times.  Single-slice confocal images were captured using a 60X objective and uv 
illumination.
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membrane.  Both PKC-/V5 and -/V5 were capable of translocation and responded 
to TPA stimulation in a manner similar to PKC-, i.e. translocation to both the plasma 
and nuclear membranes.  The ability of PKC-/V5 and PKC-/V5 to translocate in 
response to TPA stimulation suggested that these chimeras were receptive to TPA 
stimulation and could indeed find their subcellular targets and function as active 
kinases. 
 That the translocation pattern of both V5 chimeras resembles that of PKC-
indicates that the V5 domain is involved in the translocation pattern differences 
between PKC- and -. The binding domain of the PKC- RACK, p32, is not known, 
but if other RACK binding domains are an indication, both N-terminal and C-terminal 
residues are involved [66].  It would be easy to attribute PKC- translocation to the 
nuclear envelope as a consequence of PKC--specific localization within the nucleus, 
but fluorescent intensity measurements indicate that there is little difference between 
the amount of PKC- and - within the nucleus (data not shown) although it does look 
like there is increased nuclear fluorescence in PKC- and PKC-/V5 in Figure 8. 
 
Kinase Assays
In vitro kinase assays were then performed with immunoprecipitated PKCs to 
see how well PKC chimeric and truncation mutants were able to phosphorylate both 
full-length and peptide substrates.  The kinase assays were performed with 32P-labeled 
ATP to measure phosphotransfer to the substrate.  This was done by separating the 
contents of the kinase reaction via SDS PAGE and then exposing the gel to X-ray film.  
44 
The amount of 32P in the target protein band, identified by protein stain, represented the 
kinase activity in the lysate.  Figure 9 shows the results of representative kinase assay 
performed with wild-type PKC- and PKC- mutants.  Only wild-type PKC- was able 
to phosphorylate full length Histone H1 efficiently.  PKC- truncation of just 11 amino 
acids or more from the carboxyl terminus significantly reduced kinase activity, as did 
the exchange of the PKC- V5 domain for the PKC- V5 domain (Figure 9).  For each 
kinase assay Western blots and Coomassie staining of the gels were done in parallel to 
provide controls for both the amount of enzyme used (Western blot) as well as the 
amount of substrate included in the reaction (Coomassie stained gel).  In certain cases 
densitometry was also utilized as another means of visualizing substrate 
phosphorylation levels.  The densitometry in Figure 9 shows that there was indeed 
some phosphorylation above background from both the truncated as well as the 
chimeric PKC- mutants. 
 Figure 10 shows that a C-terminal deletion mutant of six amino acids from 
PKC- allows it to retain significant kinase activity against full length Histone H1, but 
a C-terminal truncation of 20 amino acids abrogates kinase activity in PKC-. As with 
its reciprocal partner, the kinase activity of the HA-tagged PKC-/V5 is also severely 
reduced.  Interestingly, wild type PKC- consistently showed lower kinase activity than 
PKC-; not coincidentally, the level of PKC- overexpression was usually below that 
of wild-type PKC- (see Figure 11 and Figure 13). 
 It is important to note that Coomassie stains of Histone H1 always show a 
doublet because the purification of Calf Thymus Histone H1 by Calbiochem yields two 
isoforms [67].  Changes in electrophoretic mobility of these isoforms were not
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Figure 9.  Kinase assay of wild-type PKC- and truncation and chimeric mutant derivatives of 
PKC-. GFP-tagged wild-type and chimeric PKC- and two C-terminal truncation mutants missing 
either the last 11 (GFP-CD11) or 24 (GFP-CD24) amino acids were immunoprecipitated from 
transiently transfected COS-7 cells with anti-GFP antibody and Protein A/G agaraose beads.  The bead-
bound enzyme was then allowed to phosphorylate Histone H1, a known PKC substrate, in the presence 
of 32P-ATP, TPA, Mg2+, PS and cold ATP for 30 min at 30°C.  The reaction contents were then run on 
two SDS-PAGE gels in parallel.  One gel was Coomassie-stained and then exposed to film.  The other 
was used for a Western blot.  Recombinant PKC- (0.1 µg) was used as a positive control and included 
in the last lane.  A. Autoradiograph of gel exposed to film.  B. Densitometric analysis of the 
autoradiograph in A.  Value of GFP alone was considered background and substracted. (IDV, integrated 
densitometry values).  C. Western blot of the kinase reaction contents stained with anti-GFP shows that 
similar amounts of PKC- were used in each assay.  D. Coomassie stain of the gel shows that equal 
amounts of Histone H1 were used.  Note that Calf Thymus Histone H1 yields two isoforms that run as a 
doublet, both bands of which were phosphorylated. 
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Figure 10.  Kinase assay of PKC-, PKC-/V5 and PKC- truncation mutants.  HA-tagged PKC-,
-/V5 and two PKC- C-terminal truncation mutants of 6 and 20 amino acids (PKC-CD6 and PKC-
CD20) were immunoprecipitated from transiently transfected CHO cells with anti-PKC- antibody and 
Protein A/G agarose beads.  The bead-bound enzyme was then allowed to phosphorylate Histone H1, 
and the kinase assay was completed under conditions identical to those previously described.  A.  
Autoradiograph showing 32P-labelled Histone H1.  B. Western blot of immunoprecipitated proteins 
stained with anti-HA antibody shows that similar amounts of HA-PKC were used in the assay.  C.  
Coomassie stain of polyacrylamide gel shows that equal amounts of Histone H1 were used in the assay. 
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observed even when strong kinase activity was apparent by autoradiogaphy.  This may 
be due in part to the 4-20 % polyacrylamide gel gradient, which may have masked real 
changes in mobility from phosphorylation.  In addition, phosphorylation was likely 
distributed between both isoforms, preventing detection of a change in mobility in any 
one specific band. 
To show that the phosphorylation of Histone H1 was PKC-specific and not the 
result of a contaminating kinase present either within the precipitated immunocomplex 
or the purified Histone H1 preparation, a PKC inhibitor was used to abrogate kinase 
activity.  As can be seen in Figure 11, GF109203X, an inhibitor of PKC-, -I-II, -, -
and -, was able to prevent phosphorylation of Histone H1 by wild-type PKC- very 
efficiently. 
So far, all constructs tested were tagged at the amino terminal portion of the 
protein.  Because it was possible that an N-terminal tag was inhibiting kinase activity 
of the enzymes, we tested the activity of two wild-type PKC- fusions proteins, one 
with a GFP tag at the N terminus and the other with a GFP tag at the protein’s C 
terminus.  As can be seen in Figure 12, both versions of wild-type PKC- were active.  
Thus it appears that the location of the tag was not a factor in PKC activity in this 
assay.  This is evident not only by the ability of both tagged versions of PKC- to 
phosphorylate Histone H1, but also by their ability to self-label with 32P at their 
autophosphorylation site (Figure 12).  The PKC-/V5 chimera and two truncated 
versions of PKC- were unable to phosphorylate Histone H1 as observed in previous 
assays.  In confirmation of this result, none of these constructs were able to 
autophosphorylate at the turn motif (Figure 12).  In the case of the PKC-/V5
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Figure 11.  Kinase assay of wild-type PKCs and the effect of a PKC-specific inhibitor.  HA-tagged 
PKC-, - and -CD6 were immunoprecipitated from transiently transfected CHO cells with anti-HA 
antibody and Protein A/G agarose beads.  The bead-bound enzyme was then allowed to react with 
Histone H1 for 15 min at 30°C in the same reaction buffer as previously used with or without 1 µM
GF109203X as indicated.  A. Autoradiograph showing 32P-labelled Histone H1.  B. Densitometric 
analysis of the autoradiograph in A (IDV, integrated densitometry values).  C. Western blot of 
immunoprecipitated proteins stained with anti-HA antibody.  D. Coomassie stain of polyacrylamide gel 
shows that equal amounts of Histone H1 were used in each reaction. 
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Figure 12.  Kinase assay with the GFP tag either N-terminal or C-terminal of the inserted PKC.  
Immunoprecipitated PKC- and PKC-/V5 with GFP tags fused either N-terminal or C-terminal were 
allowed to phosphorylate Histone H1 for 30 min at 30°C under in the same buffer and conditions 
previously described.  In addition, two N-terminally-tagged PKC- C-terminal truncation mutants were 
included as well as a C-terminally-tagged kinase-deficient PKC- construct as a negative control.  A. 
Autoradiograph showing 32P-labelled Histone H1 as well as autophophorylated PKC-. B. Western blot 
of immunoprecipitated proteins stained with anti-GFP antibody shows that similar amounts of GFP-PKC 
were used in each assay.  C. Coomassie stain of polyacrylamide gel shows that equal amounts of Histone 
H1 were used. 
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chimera, both an N-terminal GFP tag and a C-terminal GFP fusion protein were used, 
and neither was able to phosphorylate Histone H1 in vitro (Figure 12). 
 A known kinase-deficient PKC- construct was also utilized in this experiment.  
This version of PKC- is mutated at the ATP-binding site (K378R), preventing the 
enzyme from binding to ATP and, consequently, preventing phosphotransfer [68].  
Lane 2 of Figure 12 shows that this construct was unable to phosphorylate Histone H1 
or itself and served as a negative control for kinase activity. 
The in vitro kinase assays performed up to this point clearly showed that wild-
type PKC- and - were catalytically active against Histone H1, yet the kinase assay 
results for the chimeras were more difficult to interpret.  Densitometry and 
autoradiography results sometimes revealed PKC mutant activity above background 
(Figure 9) and sometimes they did not (Figure 12).  Yet based on the ability of the V5 
chimeras’ ability to translocate (Figure 8) and based on published success with PKC-
/II chimeras (see Introduction), it seemed unlikely that the PKC-/V5 and -/V5 
chimeras were completely inactive.  Translocation of PKC from the cytosol to the 
membrane is often used to define PKC activity because the membrane interaction 
provides the energy to release the pseudosubstrate domain, allowing the catalytic half 
of the molecule to interact with and phosphorylation substrate [23].  Moreover, it often 
appeared that some V5 chimeric kinase activity could be seen, but a large degree of 
background signal on the autoradiograph in lanes with the negative control complicated 
the analysis of the level of phosphorylation observed (data not shown).  Problems with 
high levels of background were often a complication when full length Myelin Basic 
Protein was used as a PKC substrate in the reaction (data not shown).  To address these 
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issues, experiments were proposed to test the mutants’ activity in an altered format and 
against other PKC substrates, including peptide targets that might pose less of a 
challenge to mutant PKC proteins, in terms of binding and/or specificity. 
A slightly varied kinase assay protocol was adopted which utilized a Protein 
Kinase C Assay Kit from Calbiochem (San Diego).  This new protocol presented a 
number of advantages.  First, the assay was slightly quicker.  The wild-type and mutant 
PKCs were immunoprecipitated and remained attached to the Protein A/G agarose 
beads as before, but the kinase reaction contents could be centrifuged through a 
streptavidin membrane filter which retained the biotinylated peptide substrate, post-
labeling.  The ultracentrifugation units could then be washed, and the level of peptide 
phosphorylation could be measured by adding the units directly to scintillation fluid 
and reading in a scintillation counter.  Not only did this allow for the ability to test any 
biotinylated target, this also made it possible to quantify the kinase activity and to 
measure it against “background” from negative controls.  The new, speedier protocol 
also provided the potential for higher throughput, multiple determinations and 
statistical analysis. 
Figure 13 shows the results of one of the first kinase assays performed this way. 
The substrate used in this case was a “pseudosubstrate” peptide (RFARKGSLRQKNV) 
designed specifically for the PKC Kinase Assay Kit.  It had been reported to be readily 
phosphorylated in vitro by all PKCs [69].  Wild-type PKC- and - were quite active 
against pseudosubstrate, while the V5 chimeras were significantly weaker.  
Importantly, both V5 chimeras were shown to have some kinase activity over the 
known kinase deficient mutant, PKC-KD.  PKC-/V5 had a mean value of 4511 
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Figure 13.  Kinase assay of wild-type and chimeric PKCs against pseudosubstrate peptide.  GFP-
tagged PKCs were immunoprecipitated from transiently transfected HEK 293 cells with anti-GFP-
antibody and Protein A/G agarose beads.  The bead-bound enzyme was then allowed to phosphorylate a 
biotinylated pseudosubstrate peptide (Calbiochem). A. Histogram of mean and standard deviation of 
scintillation counts from three separate reactions. (* indicates value is significantly different from PKC-
KD-GFP; PZ0.01) B. Western blot of an aliquot of IP product stained with anti-GFP to show relative 
amount of enzyme used in each reaction. 
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counts and PKC-/V5 had a mean value of 5108 counts, compared to KD-PKC-’s 
mean value of 2559 counts (Figure 13).  A t-test, assuming unequal variances, based 
upon three samples from each grouping proved that the differences between chimeric 
PKC activity and the kinase activity of the catalytically deficient mutant were indeed 
significant (P= 0.01 for both chimeras).  These results are qualitatively similar to those 
obtained from assays performed with full-length protein substrate.  It therefore seems 
likely that steric hindrance from full-length protein targets was not a factor in previous 
assays. 
Other peptide substrates were also tested to determine whether exchange of the 
 and  V5 domains had resulted in altered specificity as opposed to altered kinase 
activity. Again using the modified Protein Kinase C Assay Kit protocol, V5 chimeric 
kinase activity was tested against four biotinylated peptide substrates.  Based upon 
their amino acid sequence, three of these peptides, kindly donated by Stephen Shaw, 
NCI, NIH, were predicted to act either as preferred, neutral or disfavored substrates for 
PKC-. Dr. Shaw has done extensive work on the specificity of PKC isoforms and has 
established a predictive method for determining whether or not a given peptide is 
“preferred” or “disfavored” by any given PKC isoform [70].  Figure 14 shows the 
results of a kinase assay performed with peptides that cover a range of scores in 
predictive tests for PKC- substrate preference:  the FLJ20719 peptide 
(RRGRRSTKKRRR), predicted to be a preferred PKC- target, a vimentin peptide 
(SAVRLRSSVPGV) scoring low in Dr. Shaw’s predictive model for PKC-
specificity, and the BRCA1 peptide (LRKSSTRHIHA) predicted to be intermediate. 
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Figure 14.  Wild-type and chimeric PKC kinase specificity. GFP-tagged PKCs were 
immunoprecipitated from transiently transfected HEK 293 cells with anti-GFP and Protein A/G agarose 
beads.  The bead-bound enzyme was then allowed to phosphorylate a biotinylated peptide 
(Pseudosubstrate, FLJ20719, BRCA1 or Vimentin as indicated below the histogram) in the presence of 
32P-ATP, DAG, Mg2+, PS and cold ATP. A. Histogram of scintillation counts from reactions with 
different peptide substrates.  B. Western blot of an aliquot of IP product stained with anti-GFP to show 
amount of enzyme used in each reaction. 
55 
The pseudosubstrate peptide from the PKC Assay Kit (RFARKGSLRQKNV), already 
known to be a “preferred” pan-PKC substrate, was also included in this experiment. 
PKC- activity against the pseudosubstrate and FLJ20719 peptides was highest and 
PKC- activity against the vimentin-derived peptide was lowest, in accord with the 
predicted preference of each substrate.  The V5 chimeras showed weak activity against 
all four peptides.  Like PKC-, PKC-/V5 showed a slight preference for the 
pseudosubstrate peptide above the others.  PKC-/V5 showed a slight preference for 
the BRCA1-derived peptide.  Because PKC V5 chimera kinase activity seemed to be 
weak for all peptides as well as for both full length substrates tested and because the 
pattern of preference for the PKC-/V5 chimera was similar to that PKC-, it is 
unlikely that the weak kinase activity observed with the V5 chimeras in these assays is 
the result of altered substrate specificity. 
 
PKC Phosphorylation State
If reduced kinase activity in the PKC mutants was not a result of a change in 
substrate specificity, it might have been the result of a lack of phosphorylation at the 
phosphorylation priming sites.  As mentioned in the Introduction, active PKCs 
expressed in adherent mammalian cells are generally phosphorylated, to some degree, 
at all three priming sites.  Using antibodies to specific phospho-threonine and phospho-
serine residues, the phosphorylation state of the novel PKC mutants was tested. Figure 
15 shows that, whereas wild-type PKC- is phosphorylated at all three priming sites, 
PKC-/V5 and -/V5 lack phosphorylation in at least one of the priming sites.  PKC 
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Figure 15.  Phosphorylation status of wild-type and chimeric PKC- and -. GFP-tagged PKCs 
were immunoprecipitated from transiently-transfected CHO cell lysates using a rabbit anti-GFP antibody 
and assayed by Western blot.  The blot was stained with anti-GFP or phospho-specific antibodies.  The 
anti-pPKCpan antibody recognizes both PKC- and PKC- phosphorylated at the hydrophobic motif. 
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-/V5 is unphosphorylated at the activation loop and the hydrophobic motif; PKC-
/V5 is unphosphorylated at the hydrophobic motif site.  Although PKC-/V5 is 
phosphorylated at the turn motif, the level of phosphorylation at this site is reduced.  
Unfortunately, phospho-specific antibodies for the activation loop and turn motif sites 
of PKC- are not yet available, so the phosphorylation status of those sites within the 
chimeras remains unknown. 
 
Summary
PKC-/V5 and -/V5 were capable of translocation upon TPA 
stimulation and both mutants showed significantly reduced activity in in vitro kinase 
assays against multiple peptide substrates, including full length targets such as Histone 
H1 (Figure 9, Figure 10, and Figure 12) and Myelin Basic Protein (data not shown) as 
well as peptide substrates derived from PKC pseudosubstrate, BRCA1 and vimentin 
sequences (Figure 13 and Figure 14).  The PKC C-terminal truncation mutants showed 
little kinase activity against Histone H1 with one exception:  PKC-CD6 (Figure 9, 
Figure 10 and Figure 12).  Results with the PKC- truncation mutants suggest that the 
elimination of even one priming phosphorylation site severely decreased kinase 
activity, since PKC-CD6, which retains all three priming sites, consistently showed 
kinase activity, and the PKC-CD20 mutant did not (Figure 10).  Interestingly, this 
pattern did not hold for PKC- where the PKC-CD11 mutant, that also retained all 
three priming sites, displayed little, if any, kinase activity (Figure 9 and Figure 12).  It 
may be that the larger number of amino acids that follow the final priming site in PKC-
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, compared to PKC- (12 vs. 7), adds increased stability to the molecule.  Thus, the 
deletion of 11 PKC- V5 amino acids might be more disruptive than the deletion of 6 
PKC- V5 amino acids, despite the fact that the final priming site is retained in both 
mutants. 
In designing the PKC V5 truncation mutants, we expected to map the truncation 
length for loss of kinase activity, i.e., we expected at least one of the truncation mutants 
to show deficient kinase activity.  In contrast, the reduced in vitro kinase activity of the 
PKC V5 chimeric mutants was unexpected.  The results with the truncation mutants 
and the prominent role that the phosphorylation priming sites play in V5 domain 
function by virtue of their clustered location within the V5 domain led us to conclude 
that the phosphorylation status of these mutants should be addressed.  Results with 
phospho-specific antibodies showed that PKC-/V5 was missing at least two 
phosphorylations and that PKC-/V5 was unphosphorylated within at least one 
priming site motif.  This lack of phosphorylation provided a means to explain the 
apparently disparate results witnessed up to this point:  the PKC V5 chimeras’ ability 
to translocate and the reduced kinase activity witnessed in the in vitro experiments?  
Further experiments would show whether phosphorylation could be restored to the V5 
chimeras, resulting in fully “primed” mutants, and whether kinase activity could be 
rescued by “priming” PKC mutants either by inducing phoshorylation at unprimed sites 
or substituting unphoshorylated residues with glutamic acid. 
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CAN PKC ACTIVITY BE RESCUED IN PKC MUTANTS? 
 
TPA Does Not Induce Phosphorylation at Unprimed Sites in Novel PKC Chimeras
Of the many questions raised by the results of the kinase assays and 
phosphorylation status experiments, it seemed most logical to start with the following:  
was it possible to restore mutant PKC phosphorylation status to normal?  Parekh et al. 
showed that activation loop and hydrophobic motif phosphorylation of PKC- could be 
induced by the addition of TPA and serum to serum-starved cells and that this 
phosphorylation was not dependent upon kinase activity of PKC- itself [19].  In these 
experiments serum starvation and placement of HEK293 adherent cells into suspension 
media was required to induce dephosphorylation of PKC- at the activation loop and 
hydrophobic motif to start. 
In our experiments serum starvation was not required to induce 
dephosphorylation of the V5 chimeras since these sites were already unphosphorylated 
in the presence of serum.  Interestingly, 20 minute TPA stimulation of CHO-K1 cells 
that overexpressed GFP-PKCs did not induce phosphorylation at the activation loop 
site of PKC-/V5 or the hydrophobic motif of PKC-/V5 as expected (Figure 16).  It 
did, however, increase the level of phosphorylation at priming sites that were already 
phosphorylated before addition of TPA.  This was true for all primed sites in PKC-, -
and -/V5.  Thus, it appeared that TPA stimulation was capable of increasing the level 
of phosphorylation at sites that were already phosphorylated, but phorbol ester was 
unable to induce de novo phosphorylation at unprimed sites. 
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Figure 16.  Western blot analysis of TPA-stimulated phosphorylation of wild-type and chimeric 
novel PKCs. CHO cells were transiently transfected with GFP-tagged PKCs 24 hours before 
stimulation with 100 nM TPA for 20 min.  Cells were lysed and assayed by Western blotting with anti-
GFP and phospho-specific antibodies for PKC- and - priming sites, as indicated.  Approximately 15 
µg of total cell lysate was loaded in each lane.  The anti-actin panel shows that similar amounts of 
protein were loaded. 
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Can Glutamic Acid Substitution Rescue PKC Kinase Activity?
Mutation of the activation loop threonine in PKC-II, PKA or PKB to alanine 
inhibits the activity of all three kinases, whereas substitution with aspartic acid at this 
site in PKA and PKB or with glutamic acid in classical isoforms of PKC, to simulate 
the negative charge resulting from phosphorylation of threonine, resulted in the 
formation of a catalytically competent kinase [15, 16, 71, 72].  Glutamic acid 
substitution at the activation loop threonine in PKC- also resulted in a kinase-active 
molecule that was constitutively phosphorylated at the hydrophobic motif priming site 
[10].  As mentioned in the Introduction, PKC- does not require phosphorylation at 
T505, presumably because a compensatory glutamic acid nearby (E500) compensates 
for the negative charge requirement [17].  It should be noted, however, that catalytic 
activity was modest when the activation loop is not phosphorylated [18].   
In an attempt to rescue kinase activity of the V5 chimeras and truncation 
mutants, site-directed mutagenesis was employed to substitute glutamic acid for the 
unphosphorylated activation loop threonine in those constructs.  Additional mutants 
were produced that also contained a glutamic acid substitution at the unphosphorylated 
hydrophobic motif priming site within the chimeras, and these constructs were 
designated DM for “double mutants” (see Table 1).  Figure 17 shows the results of 
kinase assays with a subset of these mutants.  Kinase activity was maintained in wild-
type PKC- with single glutamic acid substitutions either at the activation loop 
(T505E) or at the hydrophobic motif (S662E) sites, but kinase activity seemed to be 
even further reduced in the PKC-/V5T505E and DM chimeric mutants compared to  
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Figure 17.  Kinase activity is not rescued by glutamic acid substitution at activation 
loop/hydrophobic motif priming sites within PKC-/V5. Wild-type PKC- and PKC-/V5 were 
mutated at the activation loop (T505E), at the hydrophobic motif (S662E) or both (DM).  These 
constructs were transiently expressed in HEK293 cells, immunoprecipitated with anti-GFP and Protein 
A/G agarose beads, and reacted against Histone H1 for 30 min at 30°C as described in Methods and 
Materials.  A. Autoradiograph of radiolabeled Histone H1.  B. Western blots of an aliquot of the same 
immunoprecipitates stained with anti-GFP to show that similar amounts of GFP-PKC constructs had 
been loaded and phospho-specific antibodies as indicated.  
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the PKC-/V5 mutant with no S/T -> E substitutions.  In addition, the negative charge 
at the activation loop of the PKC-/V5 T505E chimera was unable to induce priming 
phosphorylation at the hydrophobic motif site.  Yet all priming phosphorylations were 
maintained in wild-type PKC- with single glutamic acid substitutions at the activation 
loop and the hydrophobic motif (Figure 17). 
Similar results were seen when PKC-/V5 T566E and DM constructs were 
tested for activity. Figure 18 shows that PKC- T566E retained kinase activity while 
the PKC-/V5 T566E lost what activity PKC-/V5 had.  The PKC-/V5 DM 
construct also has no apparent kinase activity.  Interestingly, in both cases where kinase 
activity had been lost, the turn motif phosphorylation was also missing.  PKC-/V5 
T566E was also unphosphorylated at the hydrophobic motif, but the PKC- T566E 
mutant showed a level of phosphorylation at that site similar to wild-type PKC-.
Thus, glutamic acid substitution was not only unable to induce phosphorylation at the 
hydrophobic motif of the mutant of the PKC-/V5 T566E mutant, but the turn 
phosphorylation originally present in the PKC-/V5 chimera was lost.  Thus, the 
consequences of glutamic acid substitution at the activation loop of the chimeric 
construct are more severe than that for the wild-type PKC.  Activation loop glutamic 
acid substitution also did not rescue kinase activity of PKC-CD24 and, instead, 
resulted in the loss of phosphorylation at the turn motif site (data not shown). 
Since turn motif phosphorylation and kinase activity were both lost in the PKC-
/V5 activation loop and double (activation loop + hydrophobic motif) mutants, it was 
possible that this loss of phosphorylation was a major contributor to loss of kinase 
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Figure 18.  Kinase activity is not rescued by glutamic acid substitution at activation 
loop/hydrophobic motif priming sites within PKC-/V5.  Wild-type PKC- was mutated at the 
activation loop (T566E), and PKC-/V5 was mutated either at the activation loop (T566E) alone or at 
both T566 and the S662 hydrophobic motif site (DM).  These constructs were transiently expressed in 
HEK293 cells, immunoprecipitated with anti-GFP and reacted against Histone H1 for 30 min at 30°C as 
described in Methods and Materials.  A. Autoradiograph of radiolabeled Histone H1.  B. Western blots 
of an aliquot of the same immunoprecipitates stained with anti-PKC- to show that similar amounts of 
PKC were used in each assay and phospho-specific PKC antibodies as indicated. 
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activity.  PKC- and - V5 chimeric triple mutants were then utilized to see if glutamic 
acid substitution at all three priming sites would be capable of rescuing PKC kinase 
activity.  Figure 19 shows the results of this work.  When performed in triplicate 
against pseudosubstrate peptide, PKC- and - V5 chimeric triple mutants (TM) 
showed even less kinase activity than their unsubstituted chimeric constructs.  The 
mean number of counts for PKC-/V5 and -/V5 were 4206 and 5697, respectively.  
In both cases, these values are more than twice the mean of GFP alone (2021) and for 
PKC-/V5, this difference in mean is significant (P=0.01).  The mean number of 
counts for the PKC-/V5TM and -/V5TM were 2038 and 2154, respectively.  It was 
now abundantly clear that glutamic acid substitution could not rescue kinase activity 
within the context of the V5 chimeras. 
 
Lessons from Wild-type PKC- Glutamic Acid Mutants
Glutamic acid substitutions were made within wild-type PKC- at the activation 
loop (T505E), the turn motif (S643E), and the hydrophobic motif (S662E).  In addition, 
a double mutant (T505E/S662E) and triple mutant (T505E/S643E/S662E) variant were 
also obtained.  These constructs were designed as controls for the PKC- and - V5 
chimeric glutamic acid substitution mutants.  Yet kinase assays performed with these 
constructs alone were instructive.  Whereas PKC- was able to maintain kinase activity 
with a glutamic acid substitution made at any one of the three priming sites, 
substitutions made to two or more sites abrogated kinase activity (Figure 20). 
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Figure 19.  Kinase activity is not rescued by glutamic acid substitution at all three priming sites 
within PKC-/V5 and -/V5.  PKC-/V5 and -/V5 were mutated at the activation loop, the turn 
motif site and the hydrophobic motif site.  These triple mutant (TM) constructs were transiently 
expressed in HEK293 cells, immunoprecipitated with anti-GFP and reacted against a biotinylated 
pseudosubstrate peptide for 30 min at 30°C as described in Methods and Materials.  A. Means and 
standard deviations of kinase assay performed in triplicate.  (* indicates value is significantly different 
from cells expressing only GFP; PZ0.01)  B. Western blots of an aliquot of the same immunoprecipitates 
stained with anti-GFP to control  for amount of enzyme used in the reaction. 
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Figure 20.  Kinase activity of PKC- glutamic acid substitution mutants. PKC- was mutated at the 
activation loop, the turn motif site and the hydrophobic motif site individually, at both the activation 
loop and hydrophobic motif (DM) and at all three priming sites (TM).  PKCs were transiently expressed 
in HEK293 cells, immunoprecipitated with anti-GFP and reacted against a biotinylated pseudosubstrate 
peptide for 30 min at 30°C as described in Methods and Materials. (* indicates value is significantly 
different from control lysates of cells expressing kinase-dead (KD) KD-PKC-; PZ0.006) A. Means and 
standard deviations of kinase assay performed in triplicate.  B. Western blots of an aliquot of the same 
immunoprecipitates stained with anti-GFP (to control for amount of enzyme used in the reaction) and 
phospho-specific PKC antibodies. 
.
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A correlation of the kinase activity of the substitution mutants with their 
phosphorylation status proved to be quite intriguing (Figure 20).  Single glutamic acid 
substitutions maintained a fully primed status with the T505E and S643E PKC-
mutants.  However, the PKC- S662E mutant lost its priming phosphorylation at the 
activation loop site with very little consequence in kinase activity.  The PKC- DM lost 
its priming phosphorylation at the turn motif as did the PKC-/V5 DM mutant. The 
results of this experiment showed a clear requirement for negative charge at both V5 
priming sites, since without that, kinase activity was lost.  The exception is the PKC-
TM which did not have kinase activity despite the negative charges from glutamic acid 
residues at the turn and hydrophobic motifs.  However, in this case it would appear that 
the second conclusion from these results supercedes:  PKC- loses kinase activity when 
more than one priming phosphorylation site is substituted with a glutamic acid residue.  
This loss of kinase activity is likely not the result of the missing turn motif 
phosphorylation, since that is an autophosphorylation site.  Rather, the double 
substitution likely is unable to compensate for the stability provided by the larger 
phosphate groups, and the loss of phosphorylation at the turn motif is reflective of that 
fact.  It should be noted that a similar experiment performed with PKC- T710E (turn 
motif), PKC- DM (T566E/S729E) and PKC- TM (T566E/T710E/S729E) also 
showed that more than one glutamic acid substitution within a wild-type isoform 
resulted in kinase inhibition (data not shown). 
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Second Generation PKC- and - V5 Chimeras
The genomic structure of murine PKC- was published in 2003 [73], and 
although that of PKC- has not been published, the predicted exon boundaries for 
mouse PKC- are in perfect alignment with that of PKC-. This information revealed 
that the final exon of each of these isoforms lay slightly 3’ of the boundary used as the 
basis for the original PKC-/V5 and -/V5 constructs.  New PKC V5 chimeras were 
designed and made based upon the available genomic structure of PKC- to see if PKC 
function could be rescued in this manner.  These chimeras differ only slightly from 
those used heretofore, with the C4/V5 boundary newly defined as the final exon for 
each isoform (Exon 18 for PKC- and Exon 23 for PKC-).  The resulting new 
chimeras exchange the last 52 and 48 amino acids of PKC- and -, respectively, and 
thus represent an overall exchange of less sequence than the original PKC-/V5 and -
/V5 chimeras (Figure 21). 
When tested for kinase activity, these new chimeras also showed significantly 
decreased kinase activity compared to wild-type PKC- and - and levels of activity 
similar to those of the original PKC- and - V5 chimeras (Figure 22).  The 
phosphorylation status of these new V5 chimeras was difficult to ascertain; some 
Western blots revealed low levels of phosphorylation at the activation loop, turn motif 
and hydrophobic motif but the results were not consistent and could not be correlated 
to a particular cell type or context (data not shown). 
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Figure 21.  Depiction of the V5 domains of PKC- and -. Sequences shown are for the V5 domains 
as defined in the original chimeric constructs, PKC-/V5 and -/V5.  Arrows indicate the boundary of 
the final exon for each isoform.  Sequences to the right of the arrows were exchanged in the production 
of the revised V5 chimeras, PKC-/23 and -/18. 
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Figure 22.  Kinase activity is not rescued by exchange of only final exon of PKC- and -. New 
chimeras were constructed in which only the final exon of PKC- (Exon 18) and - (Exon 23) were 
exchanged, and these mutants were transiently expressed in HEK293 cells, immunoprecipitated with 
anti-GFP and protein A/G Sepharose beads and reacted against a biotinylated pseudosubstrate peptide 
for 30 min at 30°C as described in Methods and Materials A. Means and standard deviations of kinase 
assay performed in triplicate. (* indicates value is significantly different from results of lysates from 
cells expressing only GFP; PZ0.03)  B. Western blots of an aliquot of the same immunoprecipitates 
stained with anti-GFP to control for amount of enzyme used in the reaction. 
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PKC V5 Chimeras Bind to PDK-1
As mentioned in the Introduction, PDK-1 phosphorylates PKCs at the 
activation loop site.  In classical PKCs, this is the first and most important priming 
phosphorylation event; subsequent priming occurs via autophosphorylation for those 
isoforms [20, 23].  The role of PDK-1 in priming of novel PKC isoforms is also 
important, although PKC- has been shown to maintain kinase activity even when the 
activation loop site is not phosphorylated [17].  Activation loop phosphorylation of 
wild-type PKC- increased upon TPA stimulation, but the same did not occur for PKC-
/V5 (Figure 16).  One possible explanation for the lack of activation loop 
phosphorylation in the PKC V5 chimera is that PKC-/V5 is unable to bind to PDK-1.  
This would seem unlikely, since others have shown that PDK-1 could be 
immunoprecipitated with co-expressed PKC-, -I, -, -, -
 and - in HEK 293 cells 
[18].  Nevertheless, substrate protein conformation has been reported as a mechanism 
to regulate PDK-1 phosphorylation [63], and it was possible that PKC- and - V5 
chimeras possessed enough difference in conformation to prevent PDK-1 binding.  
Figure 23 shows the result of a co-immunoprecipitation experiment performed with the 
redesigned PKC- and - V5 chimeras.  PKC-/23 and PKC-/18, as well as wild-
type PKC- are able to complex with PDK-1 in CHO-K1 cells upon TPA stimulation 
(Figure 23), although the V5 of PKC- appears to bind PDK-1 less well than that of 
PKC-. Therefore, the lack of activation loop phosphorylation observed in the PKC 
V5 chimeras was not due to an inability to bind PDK-1. 
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Figure 23.  Co-immunoprecipitation of GFP-tagged PKCs with PDK-1. PKCs were transiently 
expressed in CHO cells that were stimulated with 100 nM TPA for 20 minutes.  The cells were lysed and 
PKCs were immunoprecipitated with anti-PDK-1, anti-GFP and Protein A/G sepharose beads.  Western 
blots show staining with anti-GFP and anti-PDK-1 antibodies. 
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Summary
Novel PKC V5 chimera kinase activity and phosphorylation status could not be 
rescued, either by stimulation with TPA (Figure 16), or glutamic acid substitution at 
unphosphorylated priming sites (Figure 17, Figure 18 and Figure 19).  Glutamic acid 
substitution at priming sites also did not induce phosphorylation at priming sites that 
originally lacked phosphorylation in the V5 chimeras.  Experiments performed with 
wild-type PKC- and - glutamic acid mutants revealed that more than one glutamic 
acid substitution resulted in a kinase-deficient molecule (Figure 20).  However, single 
glutamic acid substitutions at any of the three priming sites within PKC- allowed for 
retention of kinase activity and, usually, retention of a “fully-primed” molecule.  Only 
the PKC- S662E mutant demonstrated a lack of phosphorylation at one priming site 
(the activation loop site), but this did not abrogate kinase activity (Figure 20). 
New V5 chimeric constructs, which exchanged Exon 23 of PKC- for Exon 18 
of PKC-, also displayed little difference in kinase activity compared to the original V5 
chimeras (Figure 22).  In several assays, but not all, the redesigned chimeras showed 
some phosphorylation at observable priming sites, although their phosphorylation 
status was not consistent (data not shown).  Nevertheless, PKC-/23 and -/18 were 
shown to complex with PDK-1 in a co-immunoprecipitation experiment (Figure 23).  
This indicates that the PKC V5 chimeras maintain proper conformation for PDK-1 
binding and suggests that the lack of phosphorylation--at least at the activation loop 
priming site--within these mutants is a consequence of increased phosphatase activity. 
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Table 3 summarizes the results of all the kinase assays and the phosphorylation status 
of those mutants tested in this project.
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Table 3.  A summary of the phosphoryaltion status and in vitro kinase activity of the wild-type and 
mutant PKCs used in this study. ND, not determined; E, glutamic acid substituted; NA, phospho-
specific antibodies not available for that site. 
 
PKC Construct Activation 
Loop 
Turn Motif Hydrophobic 
Motif 
Kinase Activity 
PKC- +++ +++ +++ +++ 
PKC- NA NA ++ ++ 
PKC-/V5 - NA - Weak 
PKC-/V5 NA ++ - Weak 
PKC- CD11 - + ND - 
PKC- CD24 - + Deleted - 
PKC- CD54 - Deleted Deleted - 
PKC- CD6 NA NA ND + 
PKC- CD20 NA NA Deleted - 
PKC- CD50 NA Deleted Deleted ND 
PKC-/23 Varies NA Varies Weak 
PKC-/18 NA ++ Varies Weak 
PKC- T505E E ++ ++ + 
PKC- T566E E NA + Weak 
PKC-/V5 T505E E - - -
PKC-/V5 T566E E - - -
PKC- S643E + E + +
PKC- T710E NA E ND + 
PKC- S662E - ++ E + 
PKC- S729E NA NA E ND 
PKC- DM E - E -
PKC- DM E NA E - 
PKC-/V5 DM E NA E - 
PKC-/V5 DM E - E -
PKC- TM E E E -
PKC- TM E E E -
PKC-/V5 TM E E E -
PKC-/V5 TM E E E -
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DISCUSSION 
 
The Critical Role of the V5 Domain in Isoform-Specific Function
The V5 domain was shown to be essential for PKC function:  the exchange of 
the V5 region abrogated PKC-’s ability to mediate macrophage differentiation.  
However, PKC- and - V5 chimeras were unable to demonstrate the conferral of 
isoform-specific function in the 32D differentiation assay.  Nevertheless, this 
establishes the V5 domain as essential in this PKC isoform-specific function.  
Subsequent experiments sought to elucidate the structures and and mechanisms that led 
to these results.  Translocation studies performed with NIH 3T3 cells showed that the 
V5 domain is important for PKC subcellular targeting.  In this case, both PKC-/V5 
and -/V5 mimicked PKC-’s pattern of translocation to both the plasma and nuclear 
membranes.  Although PKC translocation is stimulus and isoform-specific, it seem 
reasonable to assume that the translocation pattern for wild-type PKC- is similar in 
NIH 3T3 and 32D cells for two reasons.  First, the lipophilicity of TPA drives PKC to 
membrane organelles.  Second, TPA stimulation of PKC- has shown consistent 
translocation to both the plasma and nuclear membranes in other cell types, including 
A7r5 smooth muscle cells [74] and CHO-K1 cells [75].  Therefore, if translocation 
were the determinant of PKC biological function in this assay, one would predict that 
both V5 chimeras would be capable of inducing macrophage differentiation in 32D 
cells.  Kinase assays revealed that the V5 domain was also critical for catalytic 
function.  This suggests that differences in PKC- and - translocation patterns are not 
78 
involved in their isoform specific function in this case and that translocation does not 
account for the lack of differentiation observed in 32D cells overexpressing PKC- and 
- V5 chimeras.  It also makes the point that translocation can occur in kinase-deficient 
PKCs [74], and it underscores the error in the earlier assumption that translocation of a 
particular PKC construct is a reliable indication of kinase activity. 
Differences in expression levels between overexpressed wild-type and chimeric 
PKCs also do not account for the lack of 32D cell differentiation observed.  Two pieces 
of evidence substantiate this claim.  First, PKC-/V5-overexpressing clones were 
produced that did, in fact, have expression levels equal to that of wild-type PKC-
(Figure 4), and these clones were unable to induce 32D cell differentiation upon TPA 
stimulation (Figure 6).  Second, it was possible to observe TPA stimulated macrophage 
differentiation when varying levels of wild-type PKC- were overexpressed in the 32D 
cells.  Thus, although overexpression of PKC- is required for this assay, the level of 
PKC- overexpression seems not to be critical.   
We showed earlier that apoptosis could be mediated by PKC- in A7r5 cells, 
even if a kinase-deficient PKC- mutant was utilized, as long as translocation could be 
achieved [74].  Monocyte differentiation, however, does not work the same way. Li et 
al. showed that an ATP-binding-deficient PKC- construct (K376R) was not capable of 
inducing 32D cell differentiation [68].  It therefore seems most likely that the reduced 
kinase activity of the V5 chimeras (Figure 9, Figure 10 and Figure 13) resulted in the 
inability of one or both of the V5 chimeras to induce TPA-stimulated 32D cell 
differentiation.   
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These results contrast with those reported for a PKC-/IIV5 chimeric mutant 
that demonstrated the PKC-II-specific ability to translocate to the nucleus and 
phosphorylate lamin B [54].  In addition, numerous experiments have been conducted 
on PKC-I and -II, two splice variants that differ only in their V5 domain.  These two 
isoforms are known to translocate to distinct subcellular locations when activated in the 
same cell type [55, 56] and are associated with different physiological functions [57].  
In all of these cases, PKC isoform-specific function was conferred by the V5 domain.  
It is important to note that, in these biological assays, PKC catalytic activity directly 
was not measured directly, and it is not certain that the biological functions require 
active kinases. 
Although the reduced kinase activity of the PKC- and - V5 chimeras is likely 
to be involved in the lack of isoform-specific function conferral observed in the 32D 
cell differentiation assay, it is not necessarily responsible for this phenomenon.  The 
kinase assays presented here were performed with immunoprecipitated PKCs still 
tethered to the Protein A/G agarose-antibody complex.  This bead-bound form of the 
enzyme was much less active than recombinant PKC- and - used as positive controls.  
Thus, the results of the kinase assays presented here give an indication of the activity 
of these enzymes but do not reflect their in vivo catalytic competence.  Even so, both 
the original set of PKC V5 chimeras and the redesigned, second generation versions 
were proven to be significantly more active than a kinase-deficient PKC- mutant or 
the GFP-only control (Figure 13 and Figure 22).  Therefore, it is possible that both 
chimeras were active enough in vivo to induce differentiation.  
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The incomplete conferral of isoform-specific function could instead have been 
due to altered binding specificity of the V5 chimeras or a combination of altered 
binding specificity with reduced kinase activity.  Although the kinase experiment 
results showed no change in substrate specificity, only five different substrates were 
tested.  Moreover, PKCs can form complexes with many binding partners in addition to 
their substrate targets, including RACKs and other adapter proteins important for their 
function.  Changes in binding specificity or affinity with these other proteins could 
explain how PKC-/V5 translocation could mimic that of wild-type PKC-, but
macrophage differentiation was still not induced.  It is also possible that overexpression 
of PKC- in a given cell context leads to a concomitant change in the level of 
expression and/or activity of other endogenous PKC isoforms and that this change is 
not induced by PKC-/V5 or by PKC-/V5.  Our limited knowledge of PKC binding 
partners in assays employed here and the critical role of protein-protein interactions in 
many signaling pathways make dissection of each of these possibilities a daunting—
but very important—task for the future. 
 
Lessons from PKC- and - Truncation Mutants
Experiments performed with PKC truncation mutants showed that an intact and 
functional V5 domain is essential to PKC- and - activity: loss of as few as 11 
carboxyl terminal amino acids led to abrogated kinase activity in PKC- and loss of six 
carboxyl terminal amino acids in PKC- led to reduced in vitro kinase activity.  These 
results are in agreement with a study done by Su, et al. in which a series of PKC- C-
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terminal deletion mutants revealed that deletion of 15 or more amino acids resulted in 
partial or total loss of biological activity, whereas deletion of the most carboxyl 11 
amino acids resulted in no loss of biological activity [52].  In all cases, deletion of even 
a small portion of the hydrophobic motif resulted in partial or total loss of activity.  The 
study revealed, however, that even shorter deletions that leave the hydrophobic motif 
intact can have an adverse effect on PKC function.  Both PKC-CD6 and PKC-CD11 
showed reduced in vitro kinase activity and decreased levels of overexpression 
compared to their wild-type equivalents, despite the retention of the complete 
hydrophobic motif. 
Deletion of even a small portion of the carboxyl terminus of these enzymes 
likely resulted in substantially disrupting--if not abrogating--phosphorylation at the 
hydrophobic motif priming site.  Because the epitope for the phospho-specific PKC 
“pan” antibody used to detect phosphorylation at this site is not exactly known, it is 
impossible to say what the phosphorylation status at that site is in the PKC-CD11 and 
-CD6 mutants.  At the time when the C-terminal truncation mutants were designed for 
the present study, inclusion of the serine target in the hydrophobic phosphorylation site 
was the main consideration.  This study shows for the first time that the amino acids C-
terminal to the hydrophobic motif are critical to PKC- and - function. 
The importance of priming phosphorylations in PKC function, including kinase activity 
and downregulation, is well established [15, 22, 76, 77].  Loss of phosphorylation at 
even one of the three phosphorylation priming sites could be responsible for the loss of 
kinase activity and the difficulty in achieving equal levels of expression between wild-
type and truncated PKC mutants. 
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The Critical Role of Priming Phosphorylation in PKC- and - Function
The role of priming phosphorylations in novel PKC maturation and function 
remains complex and a matter of controversy.  This work confirmed the importance of 
each of the V5 priming sites in novel PKC- and  function, for without a negative 
charge at each of the V5 priming sites, kinase activity was significantly inhibited.  Yet 
the requirement for kinase activity seems to be more than just a negative charge at PKC 
phosphorylation priming sites.  Evidence for this includes the following: 1) PKC- and 
- TM constructs were both kinase inactive despite the fact that wild-type PKC-
retained kinase activity with a single glutamic acid substitution at any one the priming 
sites, 2) Glutamic acid substitutions within the context of the PKC- and - V5 
chimeras were unable to rescue reduced kinase activity.  Of course, based upon the 
abrogated kinase activity of wild-type PKC- and - that contained glutamic acid 
substitutions at more than one priming site, one can not expect that multiple glutamic 
acid substitutions would be able to rescue the kinase activity of the novel PKC V5 
chimeras.  
Rescue of in vitro kinase activity by glutamic acid substitution at 
unphosphorylated priming sites would have left little doubt as to the cause of the 
observed reduction in activity of the V5 chimeras and truncation mutants.  
Unfortunately we now know from our experiments with multiple S/T->E substitutions 
within wild-type PKC isoforms that we could not have expected more than one 
glutamic acid substitution in PKC- and - V5 chimeras to rescue in vitro kinase 
activity.  It remains unknown whether these constructs are able to retain/regain some in 
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vivo function despite their abrogated kinase activity.  Without the certainty that a 
positive rescue result would have provided, we are left to speculate about the role of 
the phosphorylation priming sites in these constructs.  The question remains as to 
whether or not the lack of phosphorylation at these sites is symptomatic of their 
reduced in vitro kinase activity or a cause of it. 
More intriguing is the question of why PKC V5 chimeras lack priming 
phosphorylations at all.  If PKC priming begins with binding of PDK-1 to the 
unphosphorylated hydrophobic motif, and if PDK-1 is indeed the upstream kinase for 
both PKC- and -, as has been deduced from PKC/PDK-1 binding experiments and 
kinase assays, there seems to be no reason for the chimeras to lack phosphorylation at 
the activation loop site.  This study showed that PDK-1 does indeed bind to at least one 
of the V5 chimeras (Figure 23).  Co-immunoprecipitation of GFP-tagged PKCs with an 
anti-PDK-1 antibody showed that PDK-1 bound to wild-type PKC- and - as well 
PKC-/18 and -/23.  These results suggest that lack of phosphorylation at the 
activation loop site is not a result of the inability of PKC V5 chimeras to bind to PDK-
1.  Instead, future investigations should focus on potential changes in phosphatase 
activity and the access of phosphatases to the activation loop site in these mutants. 
84 
Summary
It is abundantly clear that the V5 domain is essential to nPKC- and - function.  
Even very short truncations to the carboxyl terminus of PKC- and - result in the loss 
of stable expression and a significant reduction in kinase activity in vitro. Yet while 
this loss of function is easy to observe, rescue of function by addition of the V5 domain 
from the reciprocal isoform is not easily achieved:  PKC- and - V5 chimeras are also 
more difficult to express stably and have significantly reduced kinase activity in vitro.
Nevertheless, PKC-/V5 and -/V5 remained capable of translocating upon TPA 
retain some statistically significant kinase activity.  PKC- and - V5 chimeras are 
valuable models for the study of differences in PKC maturation and activation via 
phosphorylation and protein-protein interactions. 
85 
Conclusions
1. The V5 domain is essential to PKC function.   
2.  Exchange of PKC- and - V5 domains is enough to abrogate isoform-specific 
function, but alone it is not sufficient to confer complete isoform-specific 
function. 
3. The V5 domain is clearly involved in modulation of PKC translocation and 
kinase activity. 
4. PKC V5 chimeras lack phosphorylation at critical priming sites, including the 
activation loop site. 
5. This lack of phosphorylation is likely not due to an inability to bind PDK-1 as 
PKC- and - V5 chimeras were able to co-immunoprecipitate with PDK-1 
after TPA stimulation. 
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